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ABSTRACT 
Nicotinic acetylcholine receptors (nAChRs) are pentameric, ligand-gated, cation channels 
found throughout the central and peripheral nervous system, whose endogenous ligand is 
acetylcholine, but which can also be acted upon by nicotine. The subunit compositions of 
nAChR determine their physiological and pharmacological properties, with different 
subunits expressed in different combinations or areas throughout the brain. The behavioral 
and physiological effects of nicotine are elicited by its agonistic and desensitizing actions 
selectively on neuronal nAChRs. The midbrain is of particular interest due to its population 
of nAChRs expressed on dopaminergic neurons, which are important for reward and 
reinforcement, and possibly contribute to nicotine dependence. The α6-subunit is found on 
dopaminergic neurons but very few other regions of the brain, making it an interesting drug 
target. We assayed a novel nicotinic agonist, called TI-299423 or TC299, for its possible 
selectivity for α6-containing nAChRs. Our goal was to isolate the role of α6-containing 
nAChRs in nicotine reward and reinforcement, and provide insight into the search for more 
effective smoking cessation compounds. This was done using a variety of in vitro and 
behavioral assays, aimed dually at understanding TI-299423’s exact mechanism of action 
and its downstream effects. Additionally, we looked at the effects of another compound, 
menthol, on nicotine reward. Understanding how reward is generated in the cholinergic 
system and how that is modulated by other compounds contributes to a better understand of 
our complex neural circuitry and provides insight for the future development of 
therapeutics.   
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C h a p t e r  1  
INTRODUCTION 
Nicotinic Acetylcholine Receptors (nAChRs) 
Nicotinic Acetylcholine receptors are pentameric cation channels found throughout the 
central and peripheral nervous system. Endogenously, acetylcholine (ACh) activates these 
receptors, though they can also be activated by nicotine and other pharmacological 
compounds. nAChRs are made up of alpha (1-10), beta (1-4) and, in muscular junctions, δ, 
and ε or γ subunits [1, 61]. The neuronal nicotinic subunits are α2-7 and β2-4. The diversity 
of subunit types means there are many potential combinations for composing α-only or α 
and β-containing receptors; however, some are far more common than others. The most 
common heteromeric receptor is α4β2, while the most common homomeric receptor is α7. 
The exact combination of subunits determines the sensitivity of a receptor to ACh or other 
ligands [24]. 
nAChRs in the brain are primarily expressed at presynaptic terminals [24] where they 
modulate the release of neurotransmitters such as dopamine, glutamate, serotonin, and 
GABA [13]. The role of any nAChR is determined by the type of neuron on which it is 
expressed. The expression of the α6 subunit, for example, is limited to dopaminergic 
neurons in the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc), as 
well as to the visual pathway, including the superior colliculus and a population of ganglion 
 
 
 
2 
cells in the retina [9, 36, 62]. The α4 unit, for comparison, is found on many different 
neuron types throughout most of the brain [24]. 
The α6 nAChR Subunit 
α6-containing nAChRs are an interesting focus of study and an interesting drug target 
because their expression is limited to dopaminergic neurons, which are involved in 
learning, memory, Parkinson’s disease, and reward. While α6 is only present in about half 
of the nicotinic receptors found on dopaminergic neurons, they have a large functional 
contribution to mesolimbic dopamine release [44, 48], with almost all of the dopamine 
release in the nucleus accumbens (NAc) being attributable to α6*-nAChR activation 
(where * indicates the presence of additional subunits) [48]. Dopamine’s role in learning, 
reward, and reinforcement implicates α6* receptors as a contributor to nicotine 
dependence. In fact, by using mutant mice with hypersensitive α6 subunits (α6L9’S), α6*-
nAChRs have been shown to be sufficient for Pavlovian reward conditioning for nicotine 
using conditioned place preference (CPP) [16]. Additionally, α6 null mutant mice (α6 KO) 
fail to self-administer nicotine [46]. This behavior is rescued when α6 is virally 
reintroduced to the VTA [46]. These data indicate α6*-nAChRs are a potentially useful 
target for smoking cessation compounds. 
However, studying the α6 subunit is challenging. In vitro expression of α6*-nAChRs has 
been hampered by technical difficulties in which receptors either do not form or fail to be 
trafficked to the cellular membrane [30, 32, 37]. Use of chimeric, concatameric, or mutant 
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α6 subunits has increased our ability to research these receptors in Xenopus oocytes and 
mammalian cell lines, but the external validity of data obtained using these techniques is 
still unknown.  Additionally, because only dopaminergic neurons are known to express the 
α6 subunit, and only about half of nAChRs on those neurons contain α6, isolating these 
receptors in brain slices, or their effects in the whole brain, can be equally difficult. 
There are two primary methods used to isolate the functional contribution of α6 in vivo: 
genetic manipulation and selective compounds. Genetic manipulation has been used to 
create mice with either gene disruption (α6 KO) or the addition of a mutant gain-of-
function α6 gene (α6L9’S). α6 KO mice do not express any α6*-nAChRs, whereas 
transgenic α6L9’S mice express a mutated α6 subunit, in which the Leu 9’ residue in the 
M2 domain has been mutated to a Ser, rendering the subunit hypersensitive. Because of 
their genotype, α6 KO mice do not self-administer nicotine [46], but they can still show 
reward for high doses of nicotine using CPP [52]. Mice with the α6L9’S gene, however, 
show CPP for nicotine at lower doses than their WT litter mates [16], and have an 
increased locomotor response to acute nicotine administration [52]. In addition to genetic 
manipulation, compounds that are selective for α6-containing nAChRs can be used. α-
Conotoxin MII, for example, is a nicotinic antagonist selective for α6 and α3 containing 
receptors [31]. Thus, when applied directly to the midbrain or to dopaminergic 
synaptosomes, which contain very few α3*-nAChRs, α-Conotoxin MII can be used to 
isolate the response being mediated by α6*. The use of α-Conotoxin MII is thus similar to 
using α6 KO mice. It would therefore be useful to have a compound that activated only α6-
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containing receptors: a pharmacological equivalent to α6L9’S mice. To date, however, such 
a compound has not been developed. 
The α4 nAChR Subunit 
α4β2-nAChRs are the most common neuronal nicotinic receptor subtype and are found in 
two distinct stoichiometries, (α4)3(β2)2 and (α4)2(β2)3. The (α4)2(β2)3 receptors have a 
much higher sensitivity to ACh and other agonists than the (α4)3(β2)2 receptors. Unlike 
α6*-nAChRs, α4β2-containing receptors are not localized to any single area of the brain; 
rather, they are spread throughout [24]. As a result, they have been implicated in a number 
of different effects and behaviors, including nicotine induced conditioned place preference 
[7], nicotine self-administration [45], nicotine induced dopamine release [15], nicotinic 
antinociception [60], and nicotine induced hypothermia [57, 58]. Because they are involved 
in a wide range of behaviors and found in so many brain regions, pharmacologically 
targeting α4β2*-nAChRs risks many off-target effects, making them a less appealing target 
than α6*-nAChRs. 
Perturbations in α4β2-nAChR expression are linked to disease states, most notably 
autosomal dominant nocturnal frontal lobe epilepsy, or ADNFLE. ADNFLE is caused by 
point mutations that shift the expression of α4β2-nAChRs towards the low sensitivity 
configuration [54]. The motor seizures experienced by affected individuals are attenuated 
when patients consume nicotine through cigarette smoke. This effect is believed to be 
mediated by nicotine’s actions as a pharmacological chaperone, upregulating the number of 
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high sensitivity α4β2-nAChRs expressed on the cellular membrane. This implies that the 
downstream and long-term effects of nicotinic compounds are just as, if not more, 
important as the immediate effects seen via acute administration. 
Thankfully, unlike the α6-containing receptors, α4β2*-nAChRs express readily in oocytes 
and mammalian cell lines. This makes the effects of nicotine, ACh, and other nicotinic 
compounds on these receptors much easier to identify. Additionally, certain brain areas, 
such as the cortex and thalamus, contain almost exclusively α4β2-nAChRs [24]. Thalamic 
synaptosomes or membranes from cortical neurons can thus be used to identify drug 
properties for α4β2-nAChRs without needing to block activity at other receptor types.  
Finally, both null mutant α4 KO mice (that do not express the α4 subunit) and gain-of-
function α4L9’A mice (that express hypersensitive α4 subunits) have been developed, 
aiding the study of α4 in living animals. In the case of the α4 KO mice, we can identify 
behaviors for which the α4 subunit is necessary, as they are knocked out along with the 
gene. Because the L9’A mutation renders the α4 subunits of these mice hypersensitive to 
nicotine, α4L9’A*-nAChRs can be activated at doses too low to activate any other 
receptors. α4*-nAChRs are thus sufficient for any behavior that can still be elucidated by 
such a low dose in these mice. 
Other nAChR Subunits 
Other nAChR subtypes with implications for nicotine dependence, cognition, mood, and 
disease states include α3β4*-nAChRs, α7-nAChRs, and α5*-nAChRs. The α3-subunit 
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almost always coexpresses with β4 [32]. α3β4* receptors are primarily found in the medial 
habenula (MHb) and the interpeduncular nucleus (IPN) [24] and are less sensitive to 
nicotine than α4β2 receptors. Activation of α3β4*-nAChRs has been linked to nicotine 
aversion and withdrawal. Null mutant β4 KO mice show fewer withdrawal symptoms [28], 
and mice with enhanced levels of α3β4*-nAChRs show conditioned place aversion to 
nicotine and consume less nicotine-containing water [20]. Additionally, α3β4*-nAChRs do 
not become desensitized to nicotine at the levels found in smokers [50]. This makes them 
an interesting target for smoking cessation research. 
Homomeric α7-nAChRs have recently been investigated as a target for the treatment of 
negative and cognitive symptoms of schizophrenia, as well as a potential target for 
cognitive enhancement. Antagonists for α7 induce sensory gating deficits similar to those 
seen in schizophrenics and schizophrenia model mice [38, 41]. Additionally, post-mortem 
studies in individuals with schizophrenia have revealed a decrease in α7 receptors [22]. A 
vast majority (>90%) of schizophrenics smoke [65], a behavior thought to be self-
medication. Both agonists and positive allosteric modulators of α7 are currently being 
investigated for schizophrenia treatments and/or cognitive enhancement. 
The α5-nAChR subunit is an auxiliary subunit that is selectively coexpressed with α4β2* 
and α3β4* receptors. In α4α5β2 receptors, the α5 subunit does not participate in a 
functional binding site. α4α5β2-nAChRs are more sensitive to nicotine and ACh than low 
sensitivity α4β2(non-α5) receptors, and are more permeable to Ca2+ [34, 56]. The presence 
of an α5-subunit also makes α4β2*-nAChRs less susceptible to nicotine-induced 
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upregulation [33]. About 15% of α3β4*-nAChRs in the MHb and 35% in the IPN contain 
an α5 subunit [25]. α5 KO mice continue to show conditioned place preference for nicotine 
at doses high enough to induce aversion in their wild type littermates [27], a response 
thought to be mediated by α3α5β4-nAChRs. Understanding the roles of a range of 
nAChRs, and how they are interrelated in this way, allows for better determination of drug 
targets and improved predictability of drug effects. 
Nicotine Dependence 
One of the primary motivations for studying nAChRs is to better understand nicotine 
dependence. Nicotine is the primary addictive component in tobacco products, making 
nicotine addiction a serious health issue. The US Surgeon General first linked tobacco use 
to disease over 50 years ago [59]. Regardless, today more than 10% of deaths of 
individuals over 30 are directly attributable to tobacco use [64], amounting to millions of 
fatalities each year. In fact, tobacco use is a leading cause of preventable death worldwide 
[63]. This is partially due to tobacco’s addictive properties. While about 40% of smokers 
report trying to quit in the last year, only 10% successfully abstain for a full year [23]. 
Success rates are slightly improved with medication and counseling, but they remain quite 
low. Thus, better understanding the molecular basis for nicotine dependence is imperative 
for improving smoking cessation therapies. 
Nicotine has several of actions in the brain that need to be considered when studying 
nicotine dependence. First, it directly affects nAChRs expressed on neuronal membranes, 
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both as an agonist and via desensitization. Second, nicotine is a molecular chaperone, 
affecting the number and type of receptors expressed on the membrane. Third, nicotine can 
also affect gene expression. This multitude of effects makes it challenging to achieve a 
complete understanding of nicotine dependence. 
A large proportion of research has focused on the midbrain, which is known to be highly 
involved in learning, attention, and reward [26, 35, 42, 55]. The dopaminergic system, 
specifically, is thought to encode reward and/or salience. This suggests nicotine’s effect on 
the dopaminergic system could be responsible for its habit-forming properties. Thus, α6β2* 
and α4β2*-nAChRs, both of which have been shown to mediate dopamine release [51], are 
often targeted in nicotine dependence research. Additionally, variations in the CHRNA5 
gene, which encodes for the human α5 subunit, have been linked to an increase risk of 
nicotine dependence and an increase in daily number of cigarettes smoked [3, 4]. This 
implicates α5-containing receptors, in the development of dependence and addition. 
Studying how nicotine changes receptor prevalence and gene expression is more difficult 
because it requires long term, chronic nicotine exposure. Experiments are longer and harder 
to accomplish using animal models or in vitro methods. The external validity of these 
studies is also difficult to prove. Chronic nicotine exposure in a smoker may imply decades 
of nicotine use, which is often infeasible to model or study in a laboratory environment. 
Shorter term chronic nicotine experiments must be used to determine changes in receptor 
regulation and gene expression. 
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Nicotine and Neuroprotection 
Evidence suggests that nicotine is neuroprotective against Parkinson’s disease (PD) [21, 39, 
47]. Parkinson’s disease is a neurodegenerative disorder characterized by the loss of 
dopaminergic neurons in the SNc and their projections. This results in difficulties with 
voluntary movement, including tremors, rigidity, and changes in gait or speech [29]. Later 
symptoms can include neuropsychiatric disorders, such as depression [29], impulse control 
issues [8, 29], dementia [5, 29], and executive dysfunction [5]. PD is the second most 
common neurodegenerative disorder behind Alzheimer’s disease, affecting approximately 
7 million people worldwide [39]. Currently, there is no cure for PD. The primary treatment 
for PD is Levodopa, or L-DOPA, which is metabolized into dopamine, reducing the 
severity of motor symptoms. In a majority of individuals, PD is idiopathic, though a small 
number of genetics factors may increase risk. Without knowing what causes PD, and 
without a cure, it is imperative to find ways to prevent the onset of disease. 
Several compounds have been suggested to be neuroprotective against PD, including 
caffeine [12, 39], non-steroidal anti-inflammatory drugs (NSAIDs) [39], oestrogens [39], 
and nicotine [10, 21, 39, 47]. Smoking is negatively correlated with PD but the causal 
directionality is debated. At this time, it is unclear if smoking reduces the risk for PD or if 
being at risk for PD decreases the likelihood of smoking, but the two are not necessarily 
mutually exclusive. One study showed that ease of quitting smoking was positively 
correlated with PD, suggesting that premanifest PD may include smoking cessation [49]. 
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Other studies have shown that any history of smoking at all decreases the probability of 
developing PD in the future [10, 49]. 
The mechanism by which nicotine is proposed to be neuroprotective against PD seems to 
be associated directly with nicotine’s activation of nAChRs on dopaminergic neurons, and 
the long-term potentiation of those connections that can follow. In fact, previous studies 
have suggested that α6β2*-nAChRs, which are primarily responsible for nicotine induced 
dopamine release [47], may be necessary for neuroprotection, as their presence is only 
observed when nicotine neuroprotection has occurred [47].  This suggests that ligands 
targeting α6β2*-nAChRs and, to a lesser extent, α4β2*-nAChRs in the SNc could be used 
as potential treatments for the prevention of PD. Nicotine also reduces L-DOPA-induced 
dyskinesias [47]. Though the exact nAChR subtypes responsible for that are unknown, the 
prevalence of α6β2* and α4β2*-nAChRs in the brain implicates them as possible targets 
for this as well. 
Nicotinic Acetylcholine Receptors as Pharmacological Targets 
There are many drugs known to act on nAChRs as either agonists or antagonists, including 
nicotine, varenicline, mecamylamine, cytisine, bupropion, and epibatidine. Several of these 
compounds have analgesic properties, affect mood, or are used for smoking cessation. 
Alternative nicotine delivery methods (besides tobacco use) have been FDA approved for 
smoking cessation. As previously mentioned, it can have beneficial effects on individuals 
 
 
 
11 
with schizophrenia or ADNFLE. Nicotine also has antinociceptive properties [60], though 
it is not commonly used for this and, as mentioned, may be neuroprotective against PD. 
Nicotine has been known to have antinociceptive properties for centuries [11], an effect 
mediated α4β2-nAChRs [60]. Epibatidine, a nicotinic compound found on the skin of 
poison dart frogs [19], is a potent α4β2 agonist and, thus, a potent analgesic. However, 
epibatidine also affects muscarinic ACh receptors, causing paralysis [17] and its therapeutic 
dose is very close to its toxic concentration [18], making it effectively unusable. Similar 
α4β2 agonists, such as ABT-594, have also been studied for their antinociceptive effects 
[14]. 
Varenicline is a partial agonist for α4β2-nAChRs, with an efficacy about 13% that of ACh 
[43]. While it has been FDA approved for smoking cessation, the success rate for people 
using varenicline to quit smoking was only about 10% [6], which is modest at best. 
Additionally, varenicline has several negative side effects, including abnormal dreams, 
depression, and suicidal thoughts and tendencies. In addition to its actions on the 
cholinergic system, varenicline is a potent agonist of 5-hydroxytryptamine(3) (5-HT(3)) 
receptors [40]. This off-target effect is thought to be the cause of many of the psychological 
side effects. 
Buproprion is a nicotinic antagonist and weak norepinephrine-dopamine reuptake inhibitor 
developed for use as an antidepressant. Because it works on a different system than 
selective serotonin reuptake inhibitors (SSRIs), bupropion is often used in addition to a 
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more traditional antidepressant regimen, or as the primary treatment for individuals with 
adverse reactions to SSRIs. Smokers taking bupropion for depression reported a reduction 
in nicotine craving as well as reduced nicotine withdrawal symptoms, which led to the drug 
being prescribed for smoking cessation [66]. As a smoking cessation aid, bupropion has the 
same level of efficacy as nicotine replacement therapy, and slightly lower efficacy than 
varenicline [66]. 
Like bupropion, mecamylamine is a nonselective nicotinic antagonist that has proven 
useful in the treatment of several ailments. Originally, mecamylamine was intended as a 
treatment for hypertension [2].  More recently, low doses have proven effective as smoking 
cessation treatments [53]. Mecamylamine is also currently proposed as an antidepressant. 
Phase II trials are in progress for mecamylamine as a monotherapy antidepressant, and 
phase III trials are being conducted for approval as an add-on depression treatment. The 
relationship between mood, smoking cessation, and nAChR activation is not fully 
understood, but continued study on nicotinic compounds helps form a more complete 
picture of their interaction. 
Present Research 
The exact mechanisms behind nicotine addiction are currently not well understood. 
Studying other compounds, that modulate nicotine reward and dependence, or that are 
themselves rewarding through similar mechanisms, allows us to break down the complex 
question of nicotine addiction into smaller, more easily understood pieces. To that end, this 
 
 
 
13 
thesis focuses on two such compounds: novel nicotinic agonist TI-299423 and menthol, a 
popular flavor additive for tobacco. 
In the next chapter, TI-299423 is introduced and its effects on a range of nAChRs, 
including α4β2*, α6β2*, and α3β4* are explored. Its apparent selectivity for α6*-nAChRs 
at low doses allows us to examine its rewarding properties as well as its effects on nicotine 
reinforcement. Additional data on TI-299423, not included in Chapter 2, are included in 
Chapter 3. 
Chapter 4 focuses on menthol, a different compound which, through unknown 
mechanisms, modulates the rewarding effects of nicotine. Menthol is added to some 
tobacco products, possibly making them more addictive. Chapter 4 uses conditioned place 
preference to investigate the role of chronic and acute menthol on nicotine reward, as well 
as the rewarding properties of menthol itself. Finally, Chapter 5 discusses possible 
directions for future research. 
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C h a p t e r  2  
NOVEL NICOTINIC AGONIST TI-299423 IS SELECTIVE FOR α6β2*-nAChRs AT 
LOW DOSES, POTENTIATING NICOTINE SELF-ADMINISTRATION 
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Abstract 
TI-299423 is a novel nicotinic agonist developed for its potential selectivity for nicotinic 
acetylcholine receptors (nAChRs) containing the α6 subunit (α6*-nAChRs, where * 
indicates the presence of additional subunits). Using [125I]-epibatidine binding, 86Rb+ 
efflux, [3H]-dopamine release, patch-clamp recordings, and [3H]-ACh release, we looked at 
the affinity, efficacy, and potency of TI-299423 on α6β2*, α4β2*, and α3β4* receptors. TI-
299423 is a partial agonist for α6*-nAChRs with an EC50 between 30 and 60 nM, making 
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it partially selective for this subtype at low doses. Pharmacokinetic studies were done to 
determine TI-299423’s bioavailability in mouse models, and an off-target effects screen 
was done to rule out effects on other neuronal receptor types. Locomotor behavior was 
measured in gain of function α6L9’S mice, showing TI-299423 to elicit α6β2*-mediated 
responses in living mammals. Because of the demonstrated role of α6β2*-nAChRs in 
nicotine reward and reinforcement, we looked at the similar effects of TI-299423 via 
conditioned place preference (CPP) and intravenous self-administration of nicotine. TI-
299423 was shown to potently elicit conditioned place preference in wild type (WT) mice 
at a dose 12 ng/Kg. α4 null mutant mice (α4KO) showed CPP at the same dose as WT 
mice. However, mice lacking the β2 subunit (β2 KO) and mice lacking the α6 subunit (α6 
KO) did not show CPP, indicating that TI-299423 is rewarding primarily through its 
activation of α6(non-α4)-containing receptors. To investigate TI-299423’s effect on 
nicotine reward, rats trained to self-administer nicotine on a fixed ratio 5 schedule were 
pre-injected with TI-299423 20 min prior to being allowed access to nicotine self-
administration. TI-299423 significantly increased IVSA of nicotine compared to pre-
injection with saline (F(1,7)=7.041, p < 0.05). Individually, TI-299423 pre-treatment doses 
of 0.01 mg/kg (p < 0.05) and 0.05 mg/kg (p < 0.05) significantly increased IVSA of 
nicotine compared to saline pre-treatment. Similar trends are seen when looking at active 
lever presses. We hypothesize TI-299423 is activating α6(non-α4)-nAChRs normally not 
activated by the administration of nicotine alone, increasing reward, a phenomenon that 
warrants further investigation. Additionally, TI-299423’s anxiolytic and analgesic effects 
were compared to the effects of nicotine and varenicline using marble burying and hot 
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plate, respectively. Mice given TI-299423 buried a similar number of marbles to mice 
given nicotine, significantly less than saline treated mice (p < 0.001) or varenicline treated 
mice (p < 0.001). Mice given TI-299423 also showed a similar antinociception response to 
mice given nicotine, spending significantly more time on the hot plate than when they were 
administered saline (p < 0.05) or varenicline (p < 0.001). 
Introduction 
Nicotine is the primary rewarding and addictive compound in tobacco [2, 30, 39, 43]. In 
addition, nicotine improves cognitive function and attention [27] and reduces the risk of 
Parkinson’s disease (PD) [35]. These actions of nicotine are via activation and 
desensitization of nicotinic acetylcholine receptors (nAChRs) in the brain, as well as effects 
on the number of receptors expressed [32]. Neuronal nAChRs are pentameric, ligand-gated 
cation channels made up of combinations of α2-7 and β2-4 subunits. These subunits can 
combine to make heteromeric, most commonly α4β2, or homomeric, α7, receptors. 
nAChRs are expressed primarily on presynaptic terminals where they modulate the release 
of other neurotransmitters, such as dopamine [5, 11]. Which subunits combine to form a 
given receptor determines that receptor’s pharmacological and electrophysiological 
properties, and may be indicative of its location both on the cell and in the brain. 
Both the α4 subunit and the α6 subunit co-express with β2 in the brain. β2-containing 
receptors (β2*) have been shown to play a crucial role in nicotine reward and 
reinforcement [25, 31, 46]. Rodents with β2 subunit deletions (β2KO) fail to self-
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administer nicotine [25, 31] but can be taught to self-administer cocaine [31]. Additionally, 
β2KO mice do not show conditioned place preference for nicotine [46]. α6-containing 
receptors are only found on dopaminergic neurons in the ventral tegmental area (VTA) and 
substantia nigra pars compacta (SNc), and in the visual pathway, including the superior 
colliculus and a population of retinal ganglion cells [7, 47]. Their localization alone 
suggests a large role in nicotine reward and reinforcement, as well as a possible mechanism 
of nicotine’s neuroprotection against PD. Unsurprisingly, α6* receptors have been shown 
to be sufficient for Pavlovian reward conditioning for nicotine using conditioned place 
preference [9], and mice with α6 subunit deletion (α6KO) fail to self-administer nicotine, a 
behavior that was ‘rescued’ when α6 was virally introduced to the VTA [33]. These 
characteristics make α6β2* receptors a prime target for potential new smoking cessation 
compounds, and possibly PD treatments. In contrast, while α4β2* receptors are also known 
to be important for nicotine reward and reinforcement [4, 26, 31, 33, 38, 40], they are the 
most common type of receptor in the brain [40] and are found in many different regions 
[15]. This implies that targeting α4β2* nAChRs holds a higher risk for unintended side-
effects, making those receptors less appealing as a target for smoking cessation aids and PD 
treatments. Thus, developing a compound that is selective for α6*-nAChRs, or even 
α6(non-α4)-nAChRs, could provide valuable insight into the cholinergic system, and have 
possibly beneficial therapeutic effects. 
Here, we introduce a novel nicotinic agonist, TI-299423. Using in vitro binding and release 
studies, as well as N2A-cells, we show TI-299423 to be extremely potent and somewhat 
selective for α6*-nAChRs. Additionally, data was obtained on the pharmacokinetics of TI-
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299423 to better understand its bioavailability, and a locomotor assay with mice expressing 
a hypersensitive α6 subunit (α6L9’S) was used to show that TI-299423 potently activates 
α6*-nAChRs in vivo. We hypothesized that TI-299423 would itself be rewarding, and 
would modulate the rewarding and reinforcement properties of nicotine. To first test the 
rewarding properties of TI-299423, we did CPP with several different mouse genotypes to 
determine which receptors were involved, and created CPP dose response curves for WT 
and α6L9’S mice. To test TI-299423’s effect on the rewarding properties of nicotine, we 
used it as a pre-treatment for rats trained to self-administer nicotine. Due to TI-299423’s 
effects on β2* receptors, which have previously been implicated in the anxiolytic effects of 
nicotine [1, 42], we suspected TI-299423 would have anxiolytic properties as well, which 
we tested using marble burying, and compared the results with those of nicotine and 
varenicline. Finally, because TI-299423 is an agonist for α4β2* and α3β4*-nAChRs at 
higher doses, we measured its antinociception properties using a hot plate assay and 
compared that to nicotine and varenicline as well. 
Materials and Methods 
Mice – Animal breeding, maintenance, and procedures at the California Institute of 
Technology were conducted in accordance with the guidelines of the National Institutes 
of Health and the approval of the California Institute of Technology Animal Care and 
Use Committee. Mice of the C57BL/6 strain, ages 40-180 days, were used in this study. 
After weaning at 25 days of age, same sex littermates were housed no more than 3 to a 
cage, with free access to food and water, on a 13/11-h light/dark cycle at 22⁰C. Mice of 
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the α4 subunit null mutant line [24], the α6 subunit null mutant line [6], and the 
hypersensitive α6L9’S transgenic mice [8] were bred and maintained as above and 
genotyped as previously described [6, 8, 24]. 
C57BL/6J strain mice, as well as various subunit null mutant mice on this background, 
were bred and maintained at the Institute for Behavioral Genetics, University of 
Colorado, Boulder, CO. Animal care and procedures with these mice were all in 
accordance with the National Institutes of Health and approved by the Animal Care and 
Utilization Committee of the University of Colorado, Boulder, CO. 
TI-299423, Nicotine, Mecamylamine, Varenicline – TI-299423, (E)-5-(pyrimidin-5-yl)-
1,2,3,4,7,8-hexahydroazocine (Figure 1), was synthesized by Targacept, Inc. (Winston-
Salem, NC). (˗)-Nicotine hydrogen tartrate salt and mecamylamine were purchased from 
Sigma-Aldrich (St. Louis, MO). Varenicline tartrate was synthesized by Targacept, Inc. 
(Winston-Salem, NC). All compounds were dissolved in physiological saline (0.9% 
sodium chloride). Dose concentrations refer to the free base.   
Conditioned Place Preference – The conditioned place preference apparatus is a 
rectangular cage with interior dimensions 46.5(L) x 12.7(W) x 12.7(H) cm, divided into 
three sub compartments: White and Black (each 16.8cm L) with a steel mesh and steel 
rod floor respectively, and Grey (7.2 cm L) with a solid plastic floor. Each compartment 
has a polycarbonate hinged lid for loading the animals. Guillotine doors, which can be 
fixed in the open or closed position, separate the chambers. 
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Mice were singly housed and habituated to the experimental room for 3-7 days before the 
initial testing day, and remained in the experimental room for the duration of the 
experiment. On day 1 (pre-training) mice were placed into the center chamber and 
allowed to explore the apparatus freely for 20 min. Time spent in each chamber was 
recorded, and drug pairing was determined by the least preferred chamber. On days 2, 4, 
6, and 8, mice were injected with the drug or dose of interest, and were confined to the 
drug-paired chamber for a total of 20 min. On days 3, 5, 7, and 9, mice were injected with 
saline and confined to the opposite chamber. On day 10 (post-training), mice were again 
given free access to the apparatus for 20 min, and time spent in each chamber was 
recorded. Conditioned place preference was determined by looking at the change in time 
spent in the drug paired chamber compared to the saline paired chamber from pre-
training to post-training. Mice with a severe initial bias for one chamber, defined as a bias 
of greater than 65% time spent in one conditioning chamber over the other, were 
excluded. 
Self-administration: 
Animals and Housing – All rat procedures were conducted in adherence with the 
National Institutes of Health and were approved by the Institutional Animal Care and Use 
Committee of Mt. Sinai. Male Wistar rats (n=8; Charles River Laboratories, Raleigh, 
NC) weighing 400-500g were housed in groups of 1-2 per cage in an environmentally 
controlled vivarium on a 12h reverse light-dark cycle. Prior to the commencement of 
behavioral testing, all rats were given ad-libitum access to food and water.  
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Materials – Eight operant chambers purchased from Med-Associates Inc. (East Fairfield, 
VT, USA) were used for the self-administration experiments. Operant chambers are 
equipped with an active and an inactive response lever, a cue light, a food pellet 
dispenser, and an automatic injection pump for administration of compounds via IV 
catheter. 
Surgery – Rats were first anesthetized using inhalation of 1–3% isoflurane in oxygen and 
then surgically prepared with silastic catheters in the jugular vein (Caine et al, 1993). The 
catheter was passed subcutaneously to a polyethylene assembly mounted on the animal's 
back. 
Self-administration Experiment – Prior to training, rats were food-restricted such that 
their body weight was approximately 85% that of free-feeding rats. They were then 
trained to press an active lever for 45mg food pellets on a fixed ratio 5 time-out 20s 
(FR5TO20) schedule of reinforcement. An inactive lever was also present in the operant 
box. Pressing of this lever was recorded but was not associated with scheduled 
consequence. Rats were trained using food pellets until a stable intake was reached, 
defined as more than 90 pellets earned per 1h session. Rats then responded for nicotine 
for 1h daily sessions. In accordance with the FR5TO20 schedule, five active lever presses 
resulted in delivery of a 1s nicotine infusion (0.03 mg per kg per infusion freebase), 
followed by a 20s time-out period paired with a light cue above the active lever, during 
which time the active lever was without consequence.  
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During experimental sessions, rats were given IP injections of TI-299423 at an injection 
volume of 1ml per 300g weight. 20 min after this injection, the rats were placed in the 
operant boxes for a 1h session during which time all active and inactive lever presses 
were recorded. After each session, catheters were flushed with heparin and checked for 
leaks or blockages. Each rat was tested with each of the doses (Veh, 0.025 mg/kg, 0.05 
mg/kg, and 0.08 mg/kg) using a Latin-square crossover design, with two 1-h daily 
nicotine self-administration sessions without pre-injection between experimental days to 
maintain and reinforce self-administration behavior. Several weeks later, rats were tested 
again with a pre-injection dose of TI-299423 of 0.01 mg/kg. 
Marble Burying – In an activity cage with bedding 2 inches deep, 15 marbles were 
arranged approximately 2 inches apart in a 5 by 3 marble grid. Mice were habituated to 
the experiment room for at least 2 h prior to testing. Mice were injected IP with the dose 
of interest and then placed in cage with the marbles. After 10 min, the mice were returned 
to their home cages. Marbles were counted as buried if they were at least 75% covered in 
bedding. Each mouse was tested under each experimental condition used a Latin-square 
crossover design with 3-4 days without testing in between each test day. 
Hot Plate – Mice were habituated to the experiment room for at least 2 h prior to testing, 
and injected intraperitoneally 5 min prior to being placed onto the hot plate apparatus 
(Harvard Apparatus, Holliston, MA). This is a heated metal plate surrounded by a 
plexiglass cylinder, within which the mouse is free to move (approximately 10 cm in 
diameter). The plate is set at 51⁰C-54⁰C.  The animal is removed from the plate once it 
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exhibits evidence of discomfort (such as paw shaking, paw licking, jumping, or 
vocalization) or until a cutoff time is reached (60 sec), whichever comes first. If the 
mouse urinates during the assay, it is immediately removed from the hot plate. The time 
that the mouse remains on the hot plate prior to showing signs of discomfort is recorded. 
Doses were administered using a Latin-square crossover design with 3-4 days without 
testing in between each testing day. 
Binding Studies Tissue Preparation – The methods used for preparing brain membranes 
in hypotonic buffer were similar to the methods of [20, 21]. Brain membrane preparations 
were either stored as pellets under buffer at -70⁰C or used immediately.  
[125I]-epibatidine binding – Methods for [125I]-epibatidine binding are described in [16]. 
Ki values for inhibition of binding of 100 pM [125I]-epibatidine by TI-299423 were 
determined for various nAChR subtypes using WT cortical membranes (α4β2*), IPN 
from β2KO mice (α3β4*), or striatal (ST) membranes from α4KO mice (α6β2*) by 
incubation for 2 h at room temperature followed by filtration. 1 mM (-)-nicotine tartrate 
was used to determine non-specific binding. Bound [125I]-epibatidine was determined by 
counting at 60% efficiency in a 1450 MicroBeta Trilux scintillation counter after addition 
of Optiphase SuperMix scintillation cocktail (150 ml/sample) (Perkin Elmer Life 
Sciences-Wallac Oy, Turku, Finland). 
Membrane binding data analysis – After subtraction of non-specific binding, Ki values 
were determined by a one-site fit to the inhibition equation B = B0/(1+([I]/IC50)) where B 
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is ligand bound in the presence of inhibitor at concentration [I] and B0 is ligand bound in 
the absence of inhibitor [48]. Ki values were calculated from IC50 values using the 
equation Ki = IC50/(1+(L/KD)). 
Synaptosome preparation – Regions of interest were dissected from fresh mouse brains 
and were homogenized in ice-cold isotonic sucrose (0.32 M) buffered with HEPES (5 
mM, pH 7.5). The suspension was centrifuged at 12,000 x g for 20 min and then the 
pellet was resuspended in the appropriate uptake buffer [17, 23, 37] and used 
immediately. 
[3H]-Dopamine uptake and release – Release methods of Salminen et al. (2004, 2007) 
[36, 37] were followed using crude synaptosomal pellets from striatal tissue. Superfusion 
was at room temperature with buffer (NaCl, 128 mM; KCl, 2.4 mM; CaCl2, 3.2 mM; 
MgSO4, 1.2 mM; KH2PO4, 1.2 mM; HEPES, 25 mM; pH 7.5; glucose, 10 mM; ascorbic 
acid, 1 mM; pargyline, 0.01 mM) containing 0.1% BSA, nomifensine (1 µM), to prevent 
re-uptake of dopamine, and atropine (1 µM), in order to prevent any possible activation 
of muscarinic ACh receptors, at 0.7 ml/min for 10 min before stimulation with agonist for 
20 s. Selected aliquots were perfused with α-CtxMII (50nM) for 3 min immediately 
before stimulation. This concentration of α-CtxMII is sufficient to inhibit all α6β2*-
nAChR forms present in mouse striatum [31]. Fractions (~0.1 ml) were collected every 
10s into 96-well plates using a Gilson F204 fraction collector (Middleton WI). After 
addition of 0.15 ml of Optiphase SuperMix scintillation cocktail, radioactivity was 
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determined in a 1450 MicroBeta Trilux counter (Perkin Elmer Life Sciences – Wallac 
Oy, Turku, Finland). 
[3H]-ACh uptake and release – Release methods of Grady et al. (2001) [17] were 
followed using the crude synaptosomes from IPN tissue. Uptake of [3H]-choline was by 
incubation for 30 min at 37⁰C in buffer (NaCl, 128 mM;  KCl, 2.4 mM; CaCl2, 3.2 mM; 
MgSO4, 1.2 mM; KH2PO4, 1.2 mM; HEPES, 25 mM; pH 7.5; glucose, 10 mM; 0.1% 
BSA) at 0.1 ml/mouse. Superfusion was for 10 min at 0.7 ml/min with buffer containing 
atropine (1 µM) before stimulation by agonist for 20 s. Collection of fractions and 
determination of radioactivity were as for dopamine release. 
86Rb+ efflux – Agonist-stimulated 86Rb+ efflux from synaptosomes was investigated 
using the methods of Marks et al. (1999, 2007) [22, 23]. Briefly, crude synaptosomes 
prepared from thalamus were resuspended in uptake buffer (NaCl, 140 mM; KCl, 1.5 
mM; CaCl2, 2 mM; MgSO4, 1 mM; HEPES, 25 mM; pH 7.5; glucose, 20 mM) (350 
µl/mouse thalamus). Aliquots (25 µl) of the suspension were added to 10 µl of uptake 
buffer containing 4 µCi 86Rb+ and incubated at room temperature for 30 min. Each 
sample was then collected onto filter paper (Type AE, Gelman, Ann Arbor, MI), rinsed 
once with 0.5 ml of uptake buffer, and superfused with buffer (NaCl, 135 mM; CsCl, 5 
mM; KCl, 1.5 mM; CaCl2, 2 mM; MgSO4, 1 mM; HEPES, 25 mM; pH 7.5; glucose, 20 
mM; tetrodotoxin, 50 nM; atropine 1 µM; BSA 0.1%) at 2.5 ml/min for 5 min before data 
collection began. Stimulation by agonist was for 5s. Effluent was pumped through a 200 
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µl Cherenkov cell in a β-Ram HPLC detector (IN/US Systems, Tampa, FL) to 
continuously monitor radioactivity. 
Synaptosomal function data analysis – All synaptosomal function assays were 
calculated as counts exceeding basal release determined from samples immediately 
preceding and following stimulation [17, 22, 36]. Stimulated release was normalized to 
baseline to give units of release as a fraction of baseline. Fractions significantly over 
baseline for each perfusion were summed. EC50 values were calculated by fitting data to 
the Hill equation, or two Michaelis-Menten equations when data were biphasic. IC50 
values were calculated from the inhibition equation (release = R0/(1+[An]/IC50), where 
R0= uninhibited release and [An] is the concentration of antagonist) using the nonlinear 
least squares algorithm in SigmaPlot 5.0 (Jandel Scientific, San Rafael, CA). The errors 
for the EC50, IC50 and efficacy (as maximum activity expressed as % nicotine) are errors 
generated by the least-squares computational algorithm in SigmaPlot termed “SEM”. 
This “SEM” reflects error of the curve fit for the entire data set rather than an SEM 
calculated from independent determinations of these parameters. 
Neuro-2a Cell Culture – Mouse neuroblastoma 2a (Neuro-2a) cells were cultured using 
standard techniques [18, 50]. Cells were transfected with 500 ng of each nAChR subunit. 
Plasmids were mixed with 250 µl of Opti-MEM. Lipofectamine-2000 was separately 
added to 250 µl of Opti-MEM. After 5 min at 24 oC, DNA and Lipofectamine solutions 
were mixed together and incubated for 25 min at 24 oC. The solutions were then added to 
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pre-plated Neuro-2a cells and incubated for 24 h. After 24 h, the Opti-MEM was 
removed and replaced with growth medium.  
Patch clamp recordings – For patch clamp electrophysiology, 50,000 Neuro-2a cells 
were plated onto sterilized 12 mm ø glass coverslips (Deckgläser, Prague, Czech 
Republic), placed in 35-mm culture dishes, and cultured in a humidified incubator (37 oC, 
95% air, 5% CO2). Cells were transfected as described above. Recorded cells were 
visualized with an inverted fluorescence microscope (IX71, Olympus) in either bright 
field or fluorescence (eGFP) mode using a high-pressure Hg lamp (HB-10103AF, 
Nikon). Electrophysiological signals were recorded with an Axopatch-1D amplifier 
(Axon Instruments), Digidata 1440A analog-to-digital converter (Axon Instruments), and 
pClamp 10.0 software (Axon Instruments). Patch pipettes were filled with solution 
containing (in mM): 135 K gluconate, 5 KCl, 5 EGTA, 0.5 CaCl2, 10 HEPES, 2 Mg-
ATP, and 0.1 GTP (pH was adjusted to 7.2 with Tris-base, and osmolarity was adjusted 
to 280-300 mOsm with sucrose). The resistance of patch pipettes was 2-4 MΩ for whole-
cell recordings. Junction potential was nulled just before forming a gigaseal. All 
recordings were done at 24 oC. Data were sampled at 10 kHz and filtered at 2 kHz for 
whole-cell recordings. ACh was dissolved in extracellular solution containing (in mM): 
140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose (320 mOsm, pH set to 
7.3 with Tris-base), and were puffed (0.3 s, 20 psi) onto voltage clamped Neuro-2a cells 
(holding potential (VH), -50 mV). To avoid receptor desensitization by repetitive Ach or 
TI-299423 application, we applied drugs at ≥3 min intervals, and continually perfused the 
recording chamber with extracellular solution. For concentration response studies, we 
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used a rapid superfusion system with 500 ms puffs of agonist (Octaflow II, ALA 
Scientific Instruments). 
Locomotion – Horizontal locomotor activity was recorded using an infrared photobeam 
activity cage system (San Diego Instruments; San Diego, CA). Ambulations were 
recorded when two contiguous photobeams were broken in succession, preventing 
activity from being recorded by sedentary beam breaks. Ambulation events were 
measured at four 15 s intervals per min, for 45 min. Mice were habituated to the 
experimental room for 2 h prior to the experiment. For single injection experiments, mice 
were first moved into activity cages where their baseline activity level was measured. 
After 7.5 min, mice were removed, injected with the drug of interest (100 μL/30 g body 
mass), and returned to the activity cage for the duration of the 45 min. For experiments 
involving two injections, mice were injected with the first drug of interest before being 
placed in the activity cage where their activity level was monitored. After 8 min, they 
were removed, injected with the second drug of interest, and returned to the activity cage 
for the remainder of the 45 min. 
Off-Target Effects & PK Data – Data was collected on the potential effects of TI-299423 
at 1 µM at 70 different sites in rat brain homogenate by PerkinElmer Waltham, MA (Figure 
S1). Data on the pharmacokinetics of TI-299423 was generated by Absorption Systems LP 
Exton, PA.  
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Results 
 
Figure 1: Structure of compound TI-299423 and Nicotine. 
 Affinity, Efficacy, and Potency of TI-299423 – In order to determine the effects of TI-
299423 on α4β2*, α6β2*, and α3β4*-nAChRs, in vitro testing using [125I]-epibatidine 
binding, 86Rb+ efflux, [3H]-dopamine release and [3H]-ACh release was conducted, the 
results of which can be seen in Table 1. TI-299423 has a Ki of 1.4 ±0.6 nM for α6β2*-
nAChRs. While it is only a partial agonist of these receptors, it is extremely potent, with an 
EC50 between 30 nM and 60 nM depending on the assay, at least an order of magnitude 
lower than at α4β2*-nAChRs. 
TI-299423 has a Ki value of 0.24 ± 0.04 nM at α4β2*-nAChRs, meaning it has a higher 
affinity for these receptors than any other receptors tested. TI-299423 is a full agonist of 
high sensitivity (HS) and a partial agonist of low sensitivity (LS) α4β2*-nAChRs. 
Interestingly, it appears to be more efficacious at receptors that do not contain the α5 
subunit. TI-299423 has an EC50 in the hundreds of nanomolar range for the HS and tens of 
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micromolar for the LS α4β2*-nAChRs.  TI-299423 has a Ki 18 ± 0.7 nM for α3β4*-
nAChRs. It is a full agonist of α3β4*-nAChRs with an EC50 of 8 ± 0.4 µM. Based on this 
data alone, it seemed very low doses of TI-299423 might be selective for α6*-nAChRs. 
Table 1: Affinity, Efficacy, and Potency of TI-299423 at α4β2*, α6β2*, and α3β4*-nAChRs 
Assay Name HS α4β2 LS α4β2 α4(non-α5)β2 α6β2* α6(non-α4)β2 α6β2(α5KO) α3β4* 
[125I]-Epi binding 
Ki 0.24  ± 0.04 nM  1.4 ± 0.6 nM  18 ± 0.7 nM 
86Rb+ efflux Thalamus 
% Efficacy of Nicotine 
EC50 139% 600 ± 100 nM 
32% 
14 ± 12 µM 
170% 
1,600 ± 500 nM     
86Rb+ efflux Cortex 
% Efficacy of Nicotine 
EC50 
94% 
2,000 ± 2,000 nM 
39% 
26  ± 21 µM 
170% 
2,400 ± 700 nM     
[3H]-DA release 
% Efficacy of Nicotine 
EC50 
55% 
50 ± 20 nM 
38% 
2 ± 2 µM 
112% 
500 ± 100 nM 
30% 
60 ± 40 nM  
54% 
50 ± 20nM  
Neuro-2A Cells 
EC50 101 ± 15 nM 39 ± 9 nM  
[3H]-ACh release 
% Efficacy of Nicotine, 
EC50       
100% 
8 ± 0.4 µM 
Table 1: Table for the comparison of TI-299423’s actions at α4β2*, α6β2*, and α3β4*-nAChRs. TI-299423 
is a full agonist for high sensitivity α4β2*-nAChRs and α3β4*-nAChRs, and a partial agonist for low 
sensitivity α4β2*-nAChRs and α6β2-nAChRs. TI-299423 is extremely potent at α6β2*-nAChRs with an 
EC50 in the tens of nanomolar. Additionally, TI-299423 appears to be less efficacious at α5*-nAChRs than at 
non-α5-nAChRs. 
N2A cells and patch-clamp recordings – In order to examine the functional effects of TI-
299423 on α4β2-nAChRs and α6β2β3-nAChRs without the presence of other subunits, a 
potentially confounding factor in the assays used above, data was collected via whole-cell 
patch clamp electrophysiology with Neuro-2a cells transiently expressing α4-GFPβ2DM or 
α6-GFPβ2DMβ3 nAChRs. (Figure 2A) Fitted curves for this data give an EC50 of 101 ± 15 
nM for α4-GFPβ2DM nAChRs and an EC50 of 39 ± 9 nM α6-GFPβ2DMβ3  nAChRs. The 
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Figure 2: A) Concentration response of TI-299423 on α4-GFPβ2DM nAChRs (n=5-13) and α6-GFPβ2DMβ3 
nAChRs (n=4). Fitted curves give an EC50 and nh of 101 ± 15 nM and 1.43 ± 0.27, respectively for α4-
GFPβ2DM and an EC50 and nh of 39 ± 9 nM and 1.78 ± 0.60, respectively for α6-GFPβ2DMβ3. All data are 
mean ± SEM. B) Locomotor activation assay in WT and α6L9’S mice used to assess the bioavailability and in 
vivo activity at α6*-nAChRs. Average summed locomotor activity (n=8) between min 15-35 of assay in WT 
and L9’S mice is shown in response to IP injection of saline, 0.5 µmol/kg nicotine, or 0.5 µmol/kg TI-299423, 
with and without pre-injection of 1 mg/kg mecamylamine. * indicates difference from WT and ^ indicates 
difference from saline, using two-tailed t-test. C) When administered orally, TI-299423 has a maximum 
plasma concentration of 37.5 ± 9.6 ng/ml at time 0.25 h and a calculated half-life in the plasma is 1.12 h, or 
about 67 min. When administered intraperitoneally, TI-299423 has a maximum plasma concentration of 48.5 
± 18.0 ng/ml at time 0.08 h. and a calculated half-life in the plasma of 0.17 h, or about 10 min. D) The brain-
to-plasma concentration ratio increases over time, suggesting TI-299423 enters the brain from the plasma and 
remains in the brain as the plasma concentration decreases. 
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calculated EC50 for the α6-GFPβ2DMβ3  nAChRs is significantly lower using a two-tailed 
t- test than the calculated EC50 for the α4-GFPβ2DM nAChRs, further suggesting TI-299423 
may be selective for α6*-nAChRs over α4(non-α6)*-nAChRs.  
Locomotion – To measure the in vivo activity of TI-299423 on α6*-nAChRs, a locomotor 
assay was used (Figure 2B). Between 15-35 min after being placed in a novel cage, α6L9’S 
mice showed an average of 224.3 ambulations, which is significantly higher than the 
average 102.5 ambulations shown by WT mice in that same time period (two-tailed 
unpaired t-test, p < 0.01). When α6L9’S and WT mice were pre-injected with 1 mg/kg of 
mecamylamine, a nicotinic antagonist, prior to being put in the novel cage, α6L9’S 
produced 62.3 ambulations between min 15 and 35, while WT mice produced 83.5 
ambulations. These activity data were not significantly different from one another, 
indicating mecamylamine reduces the activity of the hypersensitive receptors. 
α6L9’S mice have previously been shown to be hypersensitive to nicotine, showing 
locomotor activation as a response. Here, after a nicotine IP injection of 0.5 µmol/kg (0.08 
mg/kg), α6L9’S mice produced an average of 623.2 ambulations between min 15 and 35. 
WT mice produced 73.69 ambulations under the same conditions, which is significantly 
fewer than the L9’S mice (two-tailed unpaired t-test, p < 0.001). When pre-injected with 
mecamylamine 1 mg/kg, and then given nicotine (0.5 µmol/kg), α6L9’S mice produced an 
average of 139 ambulations and WT mice produced an average of 111 ambulations during 
min 15-35. These activity levels are not significantly different. 
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To measure the effects of TI-299423 on α6*-nAChRs, α6L9’S and WT mice were given IP 
injections of 0.5 µmol/kg. α6L9’S mice produced an average of 581.9 ambulations between 
min 15 and 35, which is significantly higher (two-tailed unpaired t-test, p<0.001) than the 
WT mice, which produced an average of 104.54 ambulations under the same conditions. 
When pre-injected with mecamylamine 1mg/kg, and then given TI-299423 0.5 µmol/kg, 
α6L9’S mice produced an average of 98 ambulations, while WT mice produced an average 
of 104.5 ambulations between min 15 and 35, showing no significant difference. 
Pharmacokinetics – To measure the bioavailability of TI-299423 in the brains of 
mammals, a study was conducted by Absorption Systems LP (Exton, PA) on the exposure 
and brain-to-plasma ratio of TI-299423 following intraperitoneal and oral administration in 
mice. Figure 2C shows the plasma concentration over time, and Figure 2D shows the brain-
to-plasma ratio over time. These data indicate that TI-299423 enters the plasma and passes 
into the brain before being metabolized. When administered IP, TI-299423 has a maximum 
plasma concentration of 48.5 ± 18.0 ng/ml at time 0.083 h and a calculated half-life in the 
plasma of 0.170 h, or 10.2 min. When administered orally, TI-299423 has a maximum 
plasma concentration of 37.5 ± 9.59 ng/ml at time 0.25 h and a calculated half-life in the 
plasma is 1.12 h, or 67.2 min. 
CPP by Genotype – Because TI-299423 showed a level of selectivity for α6*-nAChRs, we 
decided to test the rewarding properties of this drug. Mice of different genotypes were 
tested on CPP for TI-299423 at a dose of 0.012 mg/kg (figure 3A). At this dose, WT mice  
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Figure 3: Conditioned place preference responses by genotype and dose. A) Mice were trained on the CPP 
assay with TI-299423 (12 ng/kg) (n=9-23). WT and α4KO mice showed a significant change in preference 
towards the drug paired chamber after training (paired t-test between initial and final test, p < 0.001 and p < 
0.01, respectively). Genotype had a significant effect on the conditioned place preference shown 
(F(3,47)=4.809, p < 0.01). B) WT mice were trained on the CPP assay with TI-299423 at a range of doses (0 
ng/kg - 25 ng/kg) (n=8-23). WT mice showed significant CPP when compared to saline controls at a dose of 
12 ng/kg (one-tailed t-test, p < 0.05). C) α6L9’S mice were trained on the CPP assay with TI-299423 at a 
range of doses (0 ng/kg - 25 ng/kg) (n=8-10). α6L9’S mice showed significant CPP when compared to saline 
controls at doses of 1 ng/kg (one-tailed t-test, p < 0.01), 4  ng/kg (one-tailed t-test, p < 0.01), 12 ng/kg (one-
tailed t-test, p < 0.01), and 25 ng/kg (one-tailed t-test, p < 0.001). D) The average saline response of WT mice 
was subtracted from the data, and SEMs was adjusted accordingly, giving a dose response curve with a 
baseline response of 0. A Michaelis-Menten curve was fit to the data. The calculated maximum response from 
this fit is 101 ± 23 s (p < 0.05) and the calculated EC50 is 4 ± 3 ng/kg (n.s.). E) The average saline response of 
α6L9’S mice was subtracted from the data, and SEMs was adjusted accordingly, giving a dose response curve 
with a baseline response of 0. A Michaelis-Menten curve was fit to the data. The calculated maximum 
response from this fit is 125 ± 32 s (p < 0.05) and the calculated EC50 is 0.3 ± 0.7 ng/kg (n.s.). All data shown 
are mean ± SEM. 
(n=23) showed significant average CPP of 153.7 ± 31 s (two-tailed paired t-test between 
the initial and final test, p < 0.001). This reward was still present in α4KO (n=10) mice, 
who also showed significant CPP of 159.7 ± 35 s (two-tailed paired t-test between initial 
and final test, p < 0.01). α6KO (n=9) mice and β2KO (n=10) mice, however, did not show 
significant CPP, indicating that the rewarding properties of TI-299423 are α6β2*-mediated. 
Genotype had a significant effect on the amount of CPP shown (F(3,47)=4.809, p < 0.01).    
CPP Dose Effects – WT mice were tested on CPP at a range of TI-299423 doses. When 
given saline in both chambers, WT mice habituated to the initially least preferred chamber 
over the course of training, and showed a CPP of 58.4 ± 31 s (n=14) (Figure 3B). We 
controlled for this habituation by subtracting the control average from the CPP shown at 
other doses, and recalculating SEMs accordingly (Figure 3D). A  Michaelis-Menten curve 
was fit to the data to determine the EC50 and maximal response. WT mice showed a CPP 
EC50 of 4 ± 3 ng/kg and a maximal response of 101 ± 23 s (p < 0.05). α6L9’S mice, 
however, showed sensitization when trained with saline alone, resulting in CPP of -65.6 ± 
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19 s (n=9) (Figure 3C).  We controlled for this sensitization by subtracting the control 
average from the CPP shown at other doses, and recalculating SEMs accordingly (Figure 
3E). A  Michaelis-Menten curve was fit to the data to determine the EC50 and maximal 
response. α6L9’S mice showed a CPP EC50 of 0.3 ± 0.7 ng/kg (n.s.) and a maximal 
response of 125 ± 32 s (p < 0.05). Due to the limited number of doses tested, comparing the 
genotypes with reasonable power is infeasible.  
 
Figure 4: A) Rats (n=8) self-administered more nicotine when pre-injected with TI-299423 than when pre-
injected with saline (F(1,7)=7.041, p < 0.05). This increase was individually significant with pre-injections of 
0.01 mg/kg and 0.05 mg/kg (paired t-test, p < 0.05). B) Rats (n=8) pressed the active lever more times when 
pre-injected with TI-299423 versus saline (F(1,7)=9.737, p < 0.05). The increase in lever presses was 
individually significant at pre-injection doses 0.01 mg/kg and 0.05 mg/kg (paired t-test, p < 0.05). Data 
presented are mean ± SEM. 
TI-299423 and Nicotine IVSA in rats– The CPP data suggested that TI-299423 was itself 
rewarding but provided little information about TI-299423’s effects on the rewarding 
properties of nicotine. To measure that directly, we tested the self-administration of rats 
pre-injected with TI-299423. When compared with saline pre-injection, rats pre-injected 
 
 
 
44 
with TI-299423 significantly increased their intake of nicotine (F(1,7)=7.041, p < 0.05) 
(Figure 4A) and the number of times they pressed the active lever (F(1,7)=9.737, p < 0.05) 
(Figure 4B). Because each rat was tested at each dose, we can see that on an individual 
dose level rats significantly increased their nicotine intake and active lever presses after 
pre-injection with a TI-299423 dose of 0.01 mg/kg (two-tailed paired t-test of rewards: p < 
0.05; two-tailed paired t-test of active lever presses: p < 0.05) and  0.05 mg/kg (two-tailed 
paired t-test of rewards: p < 0.05; two-tailed paired t-test of active lever presses: p < 0.05). 
 
Figure 5: Anxiolytic and analgesic effects of nicotine (0.3 mg/kg), TI-299423 (0.3 mg/kg), and varenicline 
(0.3 mg/kg) as measured by marble burying and hot plate, respectively. A) The compound received had a 
significant effect on the number of marbles buried (F(3, 33)= 45.65, p < 0.001). Additionally, comparing pre-
injection with saline individually to each drug, there is a significant decrease in the number of marbles buried 
when nicotine is pre-injected (paired t-test, p < 0.001), when TI-299423 is pre-injected (paired t-test, p < 
0.001), and when varenicline is pre-injection (paired t-test, p < 0.01), as denoted by *. Comparing varenicline 
pre-injection, we see a significant difference from nicotine (paired t-test, p < 0.001) and TI-299423 (paired t-
test, p < 0.001), as denoted by ^. Data presented are mean ± SEM. B) The compound received had a 
significant effect on the number of seconds spent on the hot plate (F(3,27)=7.442, p < 0.001). Additionally, 
comparing pre-injection with saline individually to each drug, there is a significant increase in the amount of 
time spent on the hot plate when TI-299423 is pre-injected (paired t-test, p < 0.05), as denoted by *. 
Comparing varenicline pre-injection, we see a significant increase in the time spent on the hot plate from 
nicotine (paired t-test, p < 0.01) and TI-299423 (paired t-test, p < 0.001), as denoted by ^. 
Marble Burying – One property of nicotine closely related to reward is its anxiolytic 
property. To test if TI-299423 had similar effects, mice were given pre-injections of 
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nicotine, varenicline, or TI-299423 (0.3 mg/kg) and allowed to bury marbles (Figure 5A). 
The pre-injected compound had a significant effect on the number of marbles buried (F(3, 
33)= 45.65, p<0.001). When injected with saline, mice buried significantly more marbles 
when they were injected with nicotine, TI-299423, or varenicline (two-tailed paired t-test: 
p<0.001, p<0.001, p<0.01, respectively). Additionally, when injected with nicotine or TI-
299423, mice buried fewer marbles than when they were given varenicline (two-tailed 
paired t-test, p<0.001, p<0.001, respectively).  
Hot Plate – Nicotine has also been previously shown to have antinociception properties 
through activation of α4β2*, α3β4*, or α7-nAChRs. Because TI-299423 is an agonist for 
α4β2* and α3β4*-nAChRs at higher doses, we tested its analgesic properties at a dose of 
0.3 mg/kg using a hot plate assay (Figure 5B). TI-299423 produces a similar level of 
analgesia to nicotine. Mice injected with TI-299423 spent significantly longer on the hot 
plate than mice injected with saline (paired, two-tailed t-test, p < 0.05) or varenicline 
(paired, two-tailed t-test, p < 0.001). 
Discussion 
Nicotine is considered the primary rewarding component in tobacco products. The US 
Surgeon General first linked tobacco use to disease over 50 years ago [43], and yet 
tobacco use is still a leading cause of preventable death worldwide [49], partially due to 
its addictive properties. While about 40% of smokers report trying to quit at least once in 
the last 12-months, only about 10% successfully abstain for a full year [14], a rate that is 
only mildly improved by any current treatments. Nicotine has rewarding and reinforcing 
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behavioral effects through activation and desensitization of nAChRs in the central 
nervous system. β2*-nAChRs, which often combine with α4 and α6, are necessary for 
self-administration and conditioned place preference for nicotine [19, 23, 38]. 
Additionally, studies have shown that α4*-nAChRs are sufficient for nicotine conditioned 
place preference [34], but not necessary [4], and are important, if not necessary, for 
nicotine self-administration [4, 25]. α6*-nAChRs are also sufficient for nicotine CPP 
[12], but not necessary [31], and are necessary for nicotine IVSA [25]. Being able to 
isolate α6*-nAChRs over α4*-nAChRs pharmacologically could thus be beneficial in 
furthering our understanding of nicotine reward and dependence, as well as developing 
better treatments for smoking cessation.  
TI-299423 is a small, two ring compound developed by Targacept as a potentially 
selective agonist for α6*-nAChRs over α4*-nAChRs. Comparing TI-299423 to nicotine 
in Figure 1, we see the pyridine ring of nicotine has been replaced by a pyrimidine ring, a 
change that has been previously shown to increase α6* selectivity [3]. Additionally, 
nicotine’s N-methylpyrolidine ring was modified to a 1,2,3,4,7,8-hexahydroazocine for 
TI-299423. TI-299423 is slightly heavier with a molecular mass of 189.26 g/mol to 
nicotine’s 162.23 g/mol. Additionally, TI-299423 has a LogP of approximately 1.2 
compared to nicotine’s LogP of about 1.1. This suggests that TI-299423 will be able to 
enter the brain and act as an agonist on nAChRs, more specifically α6β2*. In order to 
screen for possible off-target effects, TI-299423 was put through a novascreen that 
measured its ability to bind to 70 different receptors sites at 1 µM. The novascreen 
determined that, as expected, TI-299423 binds to neuronal nicotinic receptors. It also 
 
 
 
47 
binds to ATP-sensitive potassium channels, but with a much lower affinity than at 
nicotinic sites. These were the only two receptor sites to show significant binding, 
indicating that at the doses we use off-target effects are unlikely to confound our results.  
TI-299423’s properties with respect to α6β2*, α4β2*, and α3β4*-nAChRs were measured 
using 86Rb+ efflux, [125I]-epibatidine binding, [3H]-dopamine release, patch-clamp 
recordings, and [3H]-ACh release. The results of these tests are presented in Table 1. TI-
299423 is a partial agonist for α6β2*-nAChRs and is extremely potent, with an EC50 in 
the low tens of nanomolar range. For α4β2*-nAChRs, TI-299423 is a full agonist of the 
high sensitivity and a partial agonist of the low sensitivity receptors. It’s EC50 at α4β2*-
nAChRs is in the hundreds of nanomolar, and tens of micromolar, for HS and LS, 
respectively. Using Neuro-2A cells, we were able to isolate and separate the effects of TI-
299423 on α6(non-α4)* and α4(non-α6)*-nAChRs. Previous studies have indicated that 
nicotine is more potent at α4(non-α6)β2*-nAChRs than it is at α6(non-α4)β2*, though it 
is even more potent at α4α6β2*-nAChRs [16, 36, 45]. TI-299423, on the other hand, 
appears to be more potent at α6(non-α4)β2* than at α4(non-α6)β2*-nAChRs. Because its 
EC50 is an order of magnitude lower at α6-GFPβ2DMβ3  than at α4-GFPβ2DM, low doses 
of TI-299423 may be selective as an agonist for α6*-nAChRs. 
To measure this result in behaving animals, we first had to ensure TI-299423 could enter 
the brain and activate α6*-nAChRs in live mammals. A pharmacokinetics screen was 
used to measure how TI-299423 enters the brain (Figure 2C and 2D). The 
pharmacokinetics data indicated that TI-299423 does enter the brain, a result consistent 
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with its LogP. Next, because α6*-nAChRs are known to modulate nicotine induced 
changes in locomotion [8], a locomotor assay with α6L9’S mice was used to measure TI-
299423’s ability to activate these receptors. TI-299423 was found to be as effective as 
nicotine at eliciting a locomotor response in α6L9’S mice (Figure 2B). These data, along 
with the in vitro and Neuro-2A cell data, indicate that TI-299423 enters the brain and 
activates α6β2*-nAChRs at low doses, without activating α4(non-α6)β2*. 
Because α6*-nAChRs are localized to dopaminergic neurons, we chose to investigate the 
rewarding properties of TI-299423. α6*-nAChRs have previously been shown to be 
sufficient for conditioned place preference using α6L9’S mice and a dose of 10 ng/kg [9]. 
Our understanding of the potency and selectivity of TI-299423 for α6*-nAChRs 
prompted us to use an equivalent molar dose of TI-299423 in WT mice, without the 
hypersensitive α6-subunit. Using CPP, TI-299423 is rewarding at a dose of only 12 ng/kg 
in WT mice. The β2-subunit is known to be critical for conditioned place preference and 
self-administration mediated by the cholinergic system [46]. When we trained β2KO 
mice using TI-299423, we did not observe CPP, indicating that the CPP we saw in the 
WT mice is in fact a cholinergic, and not an off-target, effect. We then tried CPP with TI-
299423 with both α6KO and α4KO mice. α6KO mice did not show CPP for TI-299423, 
but the α4 KO mice did, indicating that this behavior is mediated by α6(non-α4)β2*-
nAChRs or, at the very least, is not dependent on α6α4β2*-nAChRs.  
Additionally, we created CPP dose response curves for TI-299423 using WT and α6L9’S 
mice, as seen in Figure 3B-E. To control for potential changes in preference not mediated 
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by TI-299423, we trained mice with saline administered in both chambers as part of CPP 
training. WT mice, as expected, habituated to the least preferred chamber during training 
(Figure 3B). Surprisingly, α6L9’S mice showed sensitization towards the least preferred 
chamber, preferring it even less after training (Figure 3C). Previous studies have shown 
that α6L9’S mice do not habituate to novel environments [8]. We believe this behavior is 
an example of that phenotype. To better compare the WT and α6L9’S dose response 
curves, we transformed the data so that the saline trained mice had a CPP of 0 (Figure 
3D-E), and fitted a Michaelis-Menten curve for each genotype. The limited number of 
doses tested, unfortunately, makes comparing the coefficients of the two regressions 
problematic, as the number of degrees of freedom is quite low. However, it is apparent 
that the α6L9’S mice show CPP at much lower doses than the WT mice, further 
implicating α6*-nAChRs as the mediating factor. 
To better understand TI-299423’s effects on reward and reinforcement, we measured its 
effect on intravenous self-administration (IVSA) of nicotine. Pre-treatment with several 
different nicotinic compounds, both agonists and antagonists, including nicotine [16, 41], 
mecamylamine [16, 41], varenicline [17], and sazetidine-A [28], has been shown to 
reduce nicotine intravenous self-administration (IVSA) in rats. Rats trained to self-
administer nicotine were pre-treated via an IP injection 20 min prior to entering the IVSA 
box. When the rats received TI-299423, they self-administered significantly more 
nicotine than when they received saline (F(1,7)=7.041, p < 0.05). This was surprising, 
given the literature on nicotinic compounds and IVSA; however, such a result is not 
completely new. A low dose of varenicline has been shown to increase IVSA in certain 
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rats [13]. While the exact mechanism behind this is unknown, we hypothesize that TI-
299423 is activating α6(non-α4)β2*-nAChRs, which are not usually agonized by self-
administration due to nicotine’s higher EC50 at these sites, without altering nicotine’s 
effect on α4β2*-nAChRs, thus compounding nicotine’s rewarding effects. 
Finally, both nicotine’s anxiolytic and analgesic properties are also considered 
contributing factors to nicotine addiction. We decided to measure how TI-299423 
affected anxiety and nociception using a marble burying assay and a hot plate assay, 
respectively. Nicotine’s anxiolytic properties are primarily α4β2*-mediated [1, 42] and 
its analgesic properties are mediated by α4β2*, α3β4*, and α7-nAChRs [44]. Thus, we 
used a much higher dose of TI-299423 in these assays (0.3 mg/kg) than in the reward 
assays, in order to ensure activation of those receptors. TI-299423 is equivalent to 
nicotine in both its anxiolytic and analgesic properties, and more powerful in each than 
varenicline. Thus, TI-299423 is not selective for α6*-nAChRs at all doses, a result that 
allows it to demonstrate potentially useful properties at higher doses. 
Developing an α6*-nAChR selective agonist is important for furthering our understanding 
of the cholinergic system and its interactions with the dopaminergic system in the brain, 
and for increasing our knowledge of nicotine dependence and how to treat it. TI-299423 is 
selective for α6*-nAChRs at low doses, resulting in surprising effects on reward and 
reinforcement, including potentiating nicotine self-administration, a phenomenon that 
warrants further research. At higher doses, TI-299423 acts as an agonist for other nAChR 
subtypes, including α4β2* and α3β4*-nAChRs, allowing it to function as both an 
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anxiolytic and an analgesic in mice. Further study into this and similar compounds may 
help us develop better smoking cessation compounds, or treatments for other disorders, in 
the future. 
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SI Figure 1: TI-299423 successfully inhibited >50% of the reference radioligand for two sites: Neuronal nAChRs and ATP-sensitive 
potassium channels. 1µM TI-299423 inhibited 93.33% of the [3H]-epibatidine binding at nAChRs and 52.12% of the [3H]-
Glibenclamide binding at the ATP-sensitive potassium channels.
Table 1.  
 Competition binding on 70 target proteins tested at a concentration of 1µM TI-299423 
Inhibition Assay Name Radioligand/Substrate Hit 
12.86% Adenosine Transporter (h) [3H]-NBTI FALSE 
7.85% Adenosine, A1 [3H]CPX FALSE 
1.51% Adenosine, A2A (h) [3H]CGS 21680 FALSE 
-0.05% Adrenergic, Alpha 1A [3H]-7-MeOxy-Prazosin FALSE 
-8.31% Adrenergic, Alpha 1B [3H]-7-MeOxy-Prazosin FALSE 
6.75% Adrenergic, Alpha 2A (h) [3H]MK-912 FALSE 
-14.09% Adrenergic, Alpha 2B [3H]MK-912 FALSE 
6.28% Adrenergic, Alpha 2C (h) [3H]MK-912 FALSE 
11.21% Adrenergic, Beta 1 (h) [125I] (-) Iodocyanopindolol FALSE 
-8.25% Adrenergic, Beta 2 (h) [125]I-Iodo-cyanopindolol FALSE 
-5.87% Dopamine Transporter [3H]WIN 35,428 FALSE 
-2.94% Dopamine, D1 (h) [3H]-SCH23390 FALSE 
-21.17% Dopamine, D2s (h) [3H]-Raclopride FALSE 
-16.93% Dopamine, D3 [3H]7-OH-DPAT FALSE 
-2.44% Dopamine, D4.4 (h) [3H]-YM-09151-2 FALSE 
-2.66% GABA A, Agonist Site [3H]GABA FALSE 
11.84% GABA A, BDZ, alpha 1 site [3H]Flunitrazepam FALSE 
-2.43% GABA-B [3H]CGP 54626A FALSE 
-1.26% Glutamate, AMPA Site (Ionotropic) [3H]AMPA FALSE 
-6.93% Glutamate, Kainate Site (Ionotropic) [3H]Kainic acid FALSE 
5.46% Glutamate, MK-801 Site (Ionotropic) [3H]MK-801 FALSE 
5.51% Glutamate, NMDA Agonist Site (Ionotropic) [3H]CGP 39653 FALSE 
7.71% Glutamate, NMDA, Phencyclidine Site (Ionotropic) [3H]TCP FALSE 
4.34% Glutamate,NMDA,Glycine (Stry-insens Site) (Ionot [3H]-MDL-105,519 FALSE 
-7.63% Glycine, Strychnine-sensitive [3H]Strychnine FALSE 
15.56% Histamine, H1 [3H]Pyrilamine FALSE 
6.50% Histamine, H2 [125I]-Aminopotentidine FALSE 
5.85% Histamine, H3 [3H]N-a-MeHistamine FALSE 
-11.73% Muscarinic, M1 (hr) [3H]Scopolamine, N-Methyl FALSE 
-3.18% Muscarinic, M2 (h) [3H]Scopolamine, N-Methyl FALSE 
-4.77% Muscarinic, M3 (h) [3H]Scopolamine, N-Methyl FALSE 
-6.69% Muscarinic, M4 (h) [3H]Scopolamine, N-Methyl FALSE 
2.24% Muscarinic, M5 (h) [3H]Scopolamine, N-Methyl FALSE 
93.33% Nicotinic, Neuronal (a-BnTx insensitive) [3H]Epibatidine TRUE 
23.72% Norepinephrine Transporter [3H]Nisoxetine FALSE 
-2.12% Opioid, Delta 2 (h) [3H]-Naltrindole FALSE 
-6.43% Opioid, Mu (h) [3H]-Diprenorphine FALSE 
7.03% Serotonin Transporter [3H]Citalopram, N-Methyl FALSE 
17.60% Serotonin, 5HT1A (h) [3H]-8-OH-DPAT FALSE 
9.99% Serotonin, 5HT1D [3H]5-CT FALSE 
12.43% Serotonin, 5HT2A [3H]Ketanserin FALSE 
-2.21% Serotonin, 5HT2C [3H]Mesulergine FALSE 
7.50% Serotonin, 5HT3 [3H]GR 65630 FALSE 
-16.64% Serotonin, 5HT4 [3H]GR 113808 FALSE 
1.24% Serotonin, 5HT5A (h) [3H]-LSD FALSE 
8.87% Serotonin, 5HT6 (h) [3H]-LSD FALSE 
-2.10% Serotonin, 5HT7 (h) [3H]LSD FALSE 
-0.52% Sigma 1 [3H]-(+)-Pentazocine FALSE 
-0.65% Sigma 2 [3H]-DTG FALSE 
-3.91% Calcium Channel, Type L (Dihydropyridine Site) [3H]Nitrendipine FALSE 
-0.60% Calcium Channel, Type N [125I]-Conotoxin GVIA FALSE 
6.83% GABA, Chloride, TBOB Site [3H]TBOB FALSE 
52.12% Potassium Channel, ATP-Sensitive [3H]Glibenclamide TRUE 
-2.57% Potassium Channel, Ca2+ Act., VI [125I]Apamin FALSE 
14.46% Potassium Channel, I[Kr] (hERG) (h) [3H]Astemizole FALSE 
6.91% Sodium, Site 2 [3H]Batrachotoxin A 20-a-Benzo FALSE 
-10.86% Nitric Oxide, NOS (Neuronal-Binding) [3H]NOARG FALSE 
29.86% Leukotriene, LTB4 (BLT) [3H]LTB4 FALSE 
-8.26% Leukotriene, LTD4 (CysLT1) [3H]LTD4 FALSE 
3.14% Thromboxane A2 (h) [SQ 29,548] 3H SQ 29,548 FALSE 
24.85% Angiotensin II, AT1 (h) [125I]-(Sar1-Ile8) Angiotensin FALSE 
32.29% Bradykinin, BK2 [3H]Bradykinin FALSE 
8.93% Endothelin, ET-A (h) [125I] Endothelin-1 FALSE 
2.10% Neurokinin, NK1 [3H]Substance P FALSE 
2.16% Neuropeptide, NPY2 (h) [125I]-PYY FALSE 
21.55% Esterase, Acetylcholine Acetylthiocholine FALSE 
12.00% Phosphodiesterase, PDE4A1A (h) Fluorescent cyclic AMP FALSE 
-3.00% Phosphodiesterase, PDE5A1 (h) Fluorescent cyclic GMP FALSE 
-5.00% Kinase, Protein, PKA (h) Fluorescein-labeled peptide FALSE 
-1.00% Kinase, Protein, PKCa (h) Fluorescein-labeled peptide FALSE 
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C h a p t e r  3  
A COLLECTION OF ADDITIONAL DATA ON THE PROPERTIES OF TI-299423 
This chapter presents data related to TI-299423 (also referred to in this chapter as TC299) 
and its activities in the brain, which is supplemental to the data presented in the previous 
chapter. Necessarily, the previous chapter and submitted paper do not contain all of the data 
collected for the project. Several data sets or types were excluded either due to their 
confusing and ineffable results, their negative results, or a failure in the experimental 
procedure.  
TI-299423 has previously been shown to be selective for α6*-nAChRs (where * indicates 
the presence of other subunits) at certain doses. This selectivity results in interesting 
reinforcement effects and effects on nicotine reward. However, the in vitro data on TI-
299423 presented in Chapter 2 is not altogether clear. TI-299423 appears to be a full 
agonist for HS α4β2*-nAChRs with a potency very similar to that of α6β2*-nAChRs. 
Further investigation into the effects of the α4*-nAChRs and TI-299423 yielded interesting 
results that we are, so far, unable to explain.  
Additional Effects of TI-299423 on α4*-nAChRs 
Figure 6A shows the results of a temperature assay used to measure TI-299423’s activation 
of α4β2*-nAChRs in vivo. Vital View PDT-4000 activity and temperature telemetric 
probes (Respironics) were used. For insertion, mice were anesthetized with either 
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isoflourine or ketamine. A 1 cm incision was made across the back of the neck and the 
probe was inserted subcutaneously into the animal. The incision was then sealed with 
surgical glue. Mice were given 4-7 days to recover, before being habituated to the 
experimental room for an additional day. Temperature data was acquired at 30 s intervals 
using the Vital View software. Data was collected for an initial 30 min to establish the 
animals’ baseline temperature. Mice were then individually removed, injected with the 
drug of interest, and returned to their receiver. Post-injection, data was recorded for an 
additional 90 min. Mice were given 1 week without drug injection between each condition 
to prevent sensitization effects. 
Nicotine induced hypothermia is known to be mediated by α4* nAChRs [9]. The 
temperature figure shows the resulting maximal change in body temperature within 45 min 
after IP injection with saline, nicotine, or TI-299423 in WT and mutant α4L9’A mice, 
which have hypersensitive α4* receptors. WT mice showed no significant change in body 
temperature after injection with any compound. α4L9’A mice had an average decrease in 
body temperature of 1.97⁰C (two tailed paired t-test p < 0.001, compared to saline) after 
injection with Nicotine at a dose of 0.1 µmol/kg (0.015 mg/kg). When injected with TI-
299423 at a dose of 0.1 µmol/kg or a dose of 0.2 µmol/kg, α4L9’A mice did not show a 
significant change in body temperature. However, when TI-299423 was given at a dose of 
0.5 µmol/kg, α4L9’A mice showed an average temperature decrease of 2.0⁰C (two-tailed 
paired t-test p < 0.001, compared to Saline). This data backs up the conclusions drawn in 
Chapter 2, that TI-299423 is selective for α6*-nAChRs and not α4(non-α6)*-  
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Figure 6: Conditioned Place Preference Data and Temperature data. A) Hypothermia assay in WT and 
α4L9’A mice used to assess the bioavailability and in vivo activity at α4*-nAChRs. Average maximum 
change in temperature (n=9) in WT and L9’A mice following IP injection of saline, nicotine, or TI-299423. B) 
The efficacy and potency of TI-299423 was tested on (α4L9’A)2(β2)3 and (α4L9’A)3(β2)2 receptors 
expressed in oocytes. TI-299423 had a lower EC50 for the three alpha receptors (3.8 ± 0.1 nM) than the two 
alpha receptors (17.4 ± 0.2 nM). Additionally, TI-299423 was 76% as efficacious as ACh at the three alpha 
receptors and 35% as efficacious at the two alpha receptors. The hill coefficient for the three alpha receptors is 
1.78 ± 0.08 and for the two alpha receptors the hill coefficient is 1.53 ± 0.03. C) Mice were trained on the 
CPP assay with TI-299423 (0.012 mg/kg) (n=9-23). WT, α4KO, and α4KOx α6KO mice showed a significant 
change in preference towards the drug paired chamber after training (paired t-test between initial and final 
test, p < 0.001, p < 0.01, and p < 0.001, respectively). Genotype had a significant effect on the conditioned 
place preference shown (F(6,74)= 3.697, p < 0.01). C) WT and α6L9’S mice were trained on the CPP assay 
with TI-299423 at a range of doses (0 mg/kg – 0.025 mg/kg) (n=8-23). WT mice showed significant CPP 
when compared to saline controls at doses of 0.012 mg/kg (p < 0.05) and 0.025 mg/kg (p < 0.05). α6L9’S 
mice showed significant CPP when compared to saline controls at 0.001 mg/kg (p < 0.01), 0.004 mg/kg (p < 
0.05), 0.012 mg/kg (p < 0.05), and 0.025 mg/kg (p < 0.001). Both genotype and treatment had a significant 
effect on CPP, but the interaction did not (Genotype: F(1,99)= 14.573, p < 0.001; Treatment: F(4,99)= 3.926, p < 
0.01; Interaction: F(4,99)= 1.238, n.s.). All data shown are mean ± SEM. 
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nAChRs at low doses. However, previous studies have shown that varenicline, a partial 
agonist for α4β2*-nAChRs with an EC50 of 50 nM for the HS and 300 nM for the LS 
receptors [5], can produce hypothermia in α4L9’A mice at a dose of only 0.001 mg/kg [5]. 
TI-299423 is a full agonist at high sensitivity and a partial agonist at low sensitivity α4β2*-
nAChRs, with an EC50 of 101 nM, suggesting that TI-299423 should produce hypothermia 
at a 0.1 µmol/kg (0.015 mg/kg) if not an even lower dose. 
Exactly why TI-299423 does not induce hypothermia at 0.1 µmol/kg and instead requires a 
higher dose of 0.5 µmol/kg is unknown. One possible hypothesis is that TI- 299423 does 
not bind as well to the mutant L9’A receptor as nicotine does. This hypothesis was tested 
using oocytes, as seen in Figure 6B. We can see that TI-299423 activates the three alpha 
α4L9’Aβ2 receptors quite potently (EC50: 3.8 ± 0.1 nM) with a 76% efficacy compared to 
ACh, and the two alpha α4L9’Aβ2 slightly less potently (EC50: 17.4 ± 0.2 nM) and with a 
35% efficacy compared to ACh. Nicotine, on the other hand, has an EC50 of 230 ± 30 nM 
[4]. Based on this information, we cannot explain why TI-299423 fails to elicit 
hypothermia at lower doses.  
Conditioned Place Preference with Additional Genotypes 
The conditioned place preference (CPP) assay also showed interesting results with regards 
to α4*-nAChRs. In Chapter 2, we showed that CPP for TI-299423 (0.012 mg/kg) was 
unaffected by knocking out α4, but was eliminated by knocking out α6, leading us to 
believe that CPP at this dose was mediated by α6(non-α4)*-nAChRs. Figure 6C shows a 
 
 
 
63 
more in-depth look at the role of genotype on TI-299423 CPP. Double knock-out 
(α4KOxα6KO) mice (n=12) showed CPP of 127.3 ± 27.3 s (two-tailed paired t-test 
between initial and final test, p < 0.001). The CPP seen in the α4KOxα6KO, double knock-
out mice is likely the most confusing piece of data gathered. Unfortunately, not much is 
known about these mice and the effects of knocking out both α4 and α6. It is possible that 
these mice have an abnormally high expression of α3*-nAChRs in the midbrain, a subunit 
not generally thought to play a role there, but which has been shown to be present in small 
numbers [1, 2]. Another possibility is that α4KOxα6KO mice habituate to novel 
environments more quickly than WT mice, the opposite of what is seen in α6L9’S mice, 
and that the CPP observed is actually habituation. More information on these mice is 
needed in order to form a well-educated hypothesis. 
Mice with hypersensitive α4 (α4L9’A) (n=9) nAChRs averaged CPP of 19.7 ± 70 s (n.s.). 
The loss of CPP in the α4L9’A mice is confusing because the knock-out data suggests α4 
does not playing a role at this dose. One cause of this effect could be the change in the 
number of α4*-nAChRs found in α4L9’A mice. Mice with the α4L9’A mutation have 
previously been shown to have significantly fewer α4-nAChRs in the brain [7], meaning 
dopamine release is even more α6*-dependent, possibly shifting the CPP dose response 
curve.  
α6L9’S mice (n=9) show CPP of only 16.6 ± 16.3 s (n.s.) at a TI-299423 dose of 0.012 
mg/kg. If the CPP shown in WT mice is mediated by α6*-nAChRs, we would expect to see 
a higher level of CPP in the α6L9’S mice, not lower. This contradiction was resolved by 
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generating a CPP dose response curve for both WT and α6L9’S mice (Figure 6D). When 
given saline in both chambers, α6L9’S mice did not habituate to their initially least 
preferred chamber. Instead, their initial preference increased, indicated by negative CPP, or 
conditioned place aversion (CPA). When compared to saline, α6L9’S mice given TI-
299423 (0.012 mg/kg) showed a similar amount of CPP as their WT littermates. When 
given a TI-299423 dose of 0.025 mg/kg, however, α6L9’S mice showed even more CPP. In 
fact, looking at the dose response curve, 0.025 mg/kg looks like a secondary peak, possibly 
mediated by different receptors.  
The α4L9’A data, and the α6L9’S dose response curve, suggest a new hypothesis for how 
TI-299423 is causing CPP. As explained in Chapter 2, we believe that TI-299423 has a 
similar EC50 for α6(non-α4)*-nAChRs as it does for α6α4*-nAChRs in wild type mice. At 
a dose of 0.012 mg/kg,TI-299423 is able to activate both of these receptor types in WT 
mice, resulting in the drug’s rewarding effects. In the α6L9’S mice, only the α6(non-α4)*-
nAChRs are being activated at doses between 0.001 mg/kg and 0.012 mg/kg. At 0.025 
mg/kg, the α6α4*-nAChRs are also activating, resulting in even more CPP. What, exactly, 
is happening in the α4L9’A mice is less clear. As mentioned above, we believe the L9’A 
mutation is shifting the CPP dose response curve, likely to the left, due to the higher 
number of α6*-nAChRs in α4L9’A mice [7]. Similarly to the double knock-out mice, 
additional study is needed both on TI-299423 and on the mutant mice in order to form a 
better hypothesis.  
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Chronic TI-299423 
 
Figure 7: Behavioral effects of chronic Nicotine(1 mg/kg/h), TI-299423 (0.02 mg/kg/h), or TI-
299423+Nicotine A) Vertical time measured after withdrawal from chronic drug administration in the 
presence and absence of nicotine. Mice who received TI-299423 as all, or part, of their chronic treatment 
spent significantly more time vertical (either grooming or rearing) than mice that did not receive any TI-
299423 B) Average mouse weight before and after chronic treatment. Mice that received chronic infusions of 
only saline gained weight during the experimental period. Mice that received nicotine, or nicotine and TI-
299423 together, had no significant change in weight. Mice that received only TI-299423 chronically lost 
weight during the course of the treatment. All data shown are mean ± SEM. 
In addition to the effects of acute TI-299423 administration, we were interested in the 
chronic effects of this compound. Several mice were implanted with catheters that allowed 
chronic administration of saline, nicotine (1 mg/kg/h), TI-299423 (0.02 mg/kg/h), or 
nicotine+TI-299423 (1 mg/kg/h and 0.02 mg/kg/h, respectively) over the course of 10 days. 
The mice were then withdrawn from the treatment for several h, and tested on Y-maze and 
open field assays. Chronic TI-299423 did not have a significant effect on most measures. 
The two most interesting measures are presented in Figure 7: vertical time and weight. 
Mice withdrawn from chronic TI-299423, or from a chronic cocktail of TI-299423 and 
nicotine, spent significantly more time vertical, either grooming or rearing, in the open field 
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test than mice given saline or nicotine alone (Figure 7A). Additionally, mice given chronic 
TI-299423 lost weight during the experiment (Figure 7B). Mice given nicotine or TI-
299423 and nicotine had no change in weight. Mice given only saline gained weight. 
The vertical time measure is not currently understood. Mice given chronic TI-299423 
showed no increase in vertical count (the number of times they stood up) or in stereotypy, 
yet they spent significantly more time standing, even with an acute dose of nicotine. 
Whether this should be interpreted as either a decrease in anxiety (standing and looking 
around) or an increase in anxiety (over-grooming) is unclear, as is the molecular basis for 
such behaviors. Additional study on both the chronic effects of TI-299423, and the 
representative data from this assay, needs to be conducted.  
Chronic TI-299423’s effect on weight is not entirely surprising. Nicotine has previously 
been shown to facilitate weight loss in mice. Nicotine treated mice did not lose weight, but 
did not gain weight at the same rate as the saline treated mice. TI-299423 may be acting as 
an appetite suppressant or increasing the activity levels of the mice. Nicotine increases 
activity in α6L9’S mice via activation of α6*-nAChRs and decrease activity in WT mice 
through activation of α4*-nAChRs [3]. Because TI-299423 acts on α6*-nAChRs more 
potently that α4*-nAChRs in mice, the chronically treated mice might have higher activity 
levels. Observation during chronic treatment is necessary for testing this hypothesis. 
Finally, an interesting behavior was noted in the mice withdrawn from chronic TI-299423. 
These mice were hyperactive in their home cage, jumping and exhibiting behaviors similar 
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to the phenotype of α6L9’S mice. This behavior was highly unexpected, and therefore 
currently unquantified. Measuring home cage activity, or locomotor responses to novel 
environments, could provide better insight into these behaviors. Additional study into the 
molecular changes caused by chronic TI-299423 is also necessary.   
TI-299423 Effects on Receptor Expression 
To that end, we tested the effects of TI-299423 on α6β2β3 and α4β2-nAChR expression on 
the plasma membrane using total internal reflection fluorescence microscopy (TIRFM). 
TIRFM methods used were similar to those previously completed on cultured cortical 
neurons [6], here applied to cultured Neuro-2A cells. TIRFM allows for the visualization of 
fluorescently labeled molecules inside the cell within ~250 nm of the cell-coverslip 
interface. To obtain TIRF images, we used an inverted fluorescence microscope (IX81; 
Olympus) equipped with an Olympus Plan Apo 100X 1.45 NA oil objective and a stepper 
motor (Thorlabs) to control the position of the fiber optic and TIRF evanescent field 
illumination. TI-299423 was added to the dishes 24 h prior to imaging. Growth medium 
was exchanged for extracellular solution (ECS) (150 mM NaCl, 4 mM KCl, 10 mM 
HEPES, 2 mM MgCl2, 2 mM CaCl2, and 10 mM glucose) and adjusted to the appropriate 
pH (5.4 or 7.4) just prior to imaging. An air-cooled argon laser (IMA101040ALS; Melles 
Griot) was used to excite SEP at 488-nm. A back-illuminated EMCCD camera (iXON DU-
897) was used to capture the images. The imaging dish was acidified to a pH of 5.4 by 
perfusing the bath, normally at pH 7.4, with an otherwise identical solution adjusted to the 
lower pH. Images taken at the lower pH demarcated ER-localized nAChRs as opposed to 
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nAChRs located on the plasma membrane. Thus, PMID was determined by taking the 
difference of the initial TIRF image of each cell at pH 7.4 and the image at pH 5.4.  
Figure 8: TI-299423 upregulates α6β2β3-nAChRs on the plasma membrane. Neuro-2A cells were transfected 
with α6-SEPβ2β3 and α4-SEPβ2 nACHRs. TI-299423 was added 24 h before imaging. A) PMID was 
quantified for α6-SEPβ2β3 nACHRs. α6β2β3 nAChRs were significantly upregulated at TI-299423 
concentrations of 1 nM (one-tailed t-test, p < 0.05) and 10 nM (one-tailed t-test, p < 0.05). B) PMID was 
quantified for α4-SEPβ2 nACHRs. α4β2 nAChRs were not significantly up or down regulated at any tested 
concentration of TI-299423. 
Using this method, previous studies have shown that nicotine increases the plasma 
membrane integrated density (PMID) of α6-SEPβ2β3 at a concentration of 50 nM and 
ofα4-SEPβ2 nAChR at a concentration of 100 nM. Because TI-299423 is so much more 
potent than nicotine at both of these receptor types, we measured upregulation of α6-
SEPβ2β3 nAChRs using three concentrations (1 nM, 10 nM and 50 nM) and upregulation 
of α4-SEPβ2 nAChR using two concentration (10 nM and 50 nM). α6-SEPβ2β3 nAChRs 
treated with 1 nM exhibited a significant, 2-fold upregulation in PMID (one-tailed t-test, p 
< 0.05), and α6-SEPβ2β3 nAChRs treated with 10 nM exhibited a significant, slightly 
lower, upregulation (one-tailed t-test, p < 0.05) (Figure 8A). α4-SEPβ2 nAChRs, however, 
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did not show significant upregulation at any dose (Figure 8B). The selective upregulation 
of α6*-nAChRs could be what is causing the behaviors observed in the withdrawn mice. 
An upregulation of α6*-nAChRs, without an accompanying upregulation of α4*-nAChRs 
could result in higher levels of dopamine release. Additional study on this is needed. 
Additional Analgesia Data 
Chapter 2 also presented data on TI-299423’s analgesic effects as compared to nicotine and 
varenicline. Figure 9 elaborates on that data. First, Figure 9 includes tail flick data that was 
excluded from Chapter 2 simply because it provides no information. The tail flick 
apparatus used has several issues. It requires the experimenter to hold the mouse during the 
test, stressing the mouse and making anxiety related, rather than stress related, tail flicks  
more likely. Additionally, the apparatus is designed to automatically detect when the 
mouse flicks its tail. This sensor can be tricked by tail movements that do not remove the 
tail from the beam, resulting in the light going off and the timer stopping, or by cleaning 
fluid not remaining on the platform, resulting in the light staying on and the timer 
continuing, even when the mouse has flicked its tail away. Because of the shortcomings of 
the apparatus and the delicate nature of the experiment, reliable tail flick data was 
unattainable. 
Figure 9A also includes several additional doses of TI-299423 that were tested. 0.01 
mg/kg, 0.1 mg/kg, and 0.3 mg/kg were all tested to determine the most effective dose, after 
which the experiment was repeated with similar doses of nicotine and varenicline (Figure 
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9B). These doses give us a nice dose response curve with 0.3 mg/kg producing the highest 
level of analgesia. The exact mechanism of nicotine induced analgesia is much debated. 
Previously, α4β2*, α3β4*, and α7-nAChRs [8] have been implicated, though recently α6*-
nAChRs have been shown to be involved as well [10]. 
Figure 9: Analgesia Data A) Dose response curve for TI-299423 on hot plate and tail flick. A TI-299423 dose 
of 0.3 mg/kg significantly increases the time spent on the hot plate (p < 0.05). No effect was seen at any dose 
on tail flick. B) Hot plate and tail flick with TI-299423 (0.3 mg/kg), nicotine (0.3 mg/kg), and varenicline (0.3 
mg/kg). Again, no effect was seen on tail flick for any drug. All data shown are mean ± SEM. 
This additional data was excluded from Chapter 2, which was submitted as a manuscript to 
the journal Neuropharmacology, because it does not provide much insight into how TI-
299423 acts in the brain. Instead, much of this data leads us to new, unanswered questions. 
We still do not understand why TI-299423 fails to elicit hypothermia at low doses, nor do 
we understand the exact mechanism behind the effects of chronic TI-299423. Continuing to 
study TI-299423, both in vitro and in vivo, will hopefully lead to additional information, 
and a more complete picture of this compounds mechanisms of action in the brain.  
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C h a p t e r  4  
ACUTE AND CHRONIC MENTHOL AFFECTS REINFORCEMENT OF NICOTINE 
This chapter contains behavioral data from the following manuscript: 
Menthol alters nicotine reinforcement, nicotinic receptor number, and  nicotinic receptor 
assembly. Henderson BJ, Wall TR, Henley BM, Kim CH, Nichols WA, Xiao C, Lester 
HA. (Submitted to Neuron, 2015) 
Abstract 
Smokers of menthol cigarettes have lower cessation rates than smokers of non-menthol 
cigarettes. This could be due to menthol potentiating the reinforcing effects of nicotine. To 
test this, I used conditioned place preference to measure reinforcement for nicotine and for 
a cocktail containing both menthol and nicotine. For both a nicotine dose of 0.5 mg/kg and 
0.25 mg/kg, the addition of menthol significantly increased the change in preference 
towards the drug-paired chamber. Chronic menthol prior to nicotine CPP was also used. 
Chronic exposure to menthol reduced nicotine CPP.  
Introduction 
The US Surgeon General first linked tobacco use to disease over 50 years ago [14]. Today, 
tobacco related disease is still one of the leading causes of preventable death in the world. 
The primary addictive compound in tobacco is nicotine, which acts on nicotinic 
acetylcholine receptors (nAChRs) in the brain. Chronic nicotine has been shown to 
upregulate nAChRs containing the β2 subunit (β2*-nAChRs, where the * denotes the 
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presence of other subunits) [3, 4, 7, 9, 10, 13], which combines with α4 and α6 subunits on 
dopaminergic neurons [8, 11, 15]. The increase in these receptors enhances the dopamine 
pathway, one possible molecular basis for nicotine dependence.  
Menthol is the sole remaining flavor additive that is legal in cigarettes in the US. Menthol 
cigarette smokers have much lower cessation rates than smokers of non-menthol cigarettes 
[1, 5], though it is unclear exactly what causes this, whether it potentiates dependence or 
withdrawal, or alters the metabolism of nicotine. Smokers of menthol containing cigarettes 
have higher levels of β2*-nAChR upregulation than smokers of non-menthol cigarettes [4]. 
Research is currently being done to determine if menthol itself causes upregulation, or if it 
is simply potentiating nicotine’s effects. One suggestion has been that menthol decreases 
airway irritation caused by cigarette smoke, allowing smokers of menthol cigarettes to 
inhale more nicotine. This hypothesis is refuted by Ashley, et. al.[2] who found that 
menthol smokers have no increase in nicotine exposure despite reduced sensory irritation.  
In addition to causing upregulation, menthol’s effects on β2*-nAChRs could imply that it is 
itself rewarding without the presence of nicotine. More importantly, since menthol 
dependence is not a major public health concern, understanding how the addition of 
menthol affects reward and reinforcement for nicotine could provide insight into why 
smokers of menthol cigarettes have lower cessation rates. We hypothesized that menthol 
potentiates the rewarding properties of nicotine. This hypothesis was tested using a 
Pavlovian reward conditioning assay called conditioned place preference (CPP).  
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Materials and Methods 
Mice – Animal breeding, maintenance, and procedures at the California Institute of 
Technology were conducted in accordance with the guidelines of the National Institutes of 
Health and the approval of the California Institute of Technology Animal Care and Use 
Committee. Mice of the C57BL/6 strain, ages 40-180 days, were used in this study. After 
weaning at 25 days of age, same sex littermates were housed no more than 3 to a cage, with 
free access to food and water, on a 13/11-h light/dark cycle at 22⁰C.  
Nicotine, Menthol – (-)-Nicotine hydrogen tartrate salt and (±)-Menthol were purchased 
from Sigma-Aldrich (St. Louis, MO). All dose concentrations refer to the free base. 
Chronic Administration – Model 1002 or 1004 osmotic mini-pumps were obtained from 
Alzet (Cupertino, CA). 48 h prior to implantation, pumps were loaded with freshly made 
vehicle or (±)-Menthol to deliver at 1 mg/kg/hr. The pre-incubation period ensures the 
pumps reach the desired pump rate before surgery is performed. Surgical procedures for 
implantation have been previously described [6, 10]. 
Conditioned Place Preference – The conditioned place preference apparatus is a 
rectangular cage with interior dimensions 46.5(L) x 12.7(W) x 12.7(H) cm, divided into 
three sub compartments: White and Black (each 16.8cm L) with a steel mesh and steel rod 
floor, respectively, and Grey (7.2 cm L) with a solid plastic floor. Each compartment has a 
polycarbonate hinged lid for loading the animals. Guillotine doors, which can be fixed in 
the open or closed position, separate the chambers. 
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Mice were singly housed and habituated to the experimental room for 3-7 days before the 
initial testing day, and remained in the experimental room for the duration of the 
experiment. On day 1 (pre-training) mice were placed into the center chamber and allowed 
to explore the apparatus freely for 20 min. Time spent in each chamber was recorded, and 
drug pairing was determined by random selection. On days 2, 4, 6, and 8, mice were 
injected with the drug or dose of interest, and were confined to the drug-paired chamber for 
a total of 20 min. On days 3, 5, 7, and 9, mice were injected with saline and confined to the 
opposite chamber. On day 10 (post-training), mice were again given free access to the 
apparatus for 20 min, and time spent in each chamber was recorded. Conditioned place 
preference was determined by looking at the change in time spent in the drug paired 
chamber compared to the saline paired chamber from pre-training to post-training. Mice 
with a severe initial bias for one chamber, defined as a bias of greater than 65% time spent 
in one conditioning chamber over the other, were excluded. 
Results 
CPP was measured for nicotine 0.25 mg/kg and 0.5 mg/kg without and without the addition 
of 1 mg/kg menthol (Figure 10A). Mice trained with only nicotine showed aversion of 
107.6 s to the drug paired chamber at a dose of 0.25 mg/kg and preference of 109.2 s for 
the drug paired chamber at a dose of 0.5 mg/kg. When Menthol (1 mg/kg) was included in 
the training cocktail, mice showed a preference of 114.0 s and 244.7 s for the drug-paired 
chamber at nicotine doses of 0.25 mg/kg and 0.5 mg/kg, respectively.  
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Mice trained with a nicotine dose of 0.25 mg/kg and menthol (1 mg/kg) showed 
significantly more conditioned place preference than mice trained with nicotine (0.25 
mg/kg) alone (two-tailed t-test, p < 0.01). Additionally, mice trained with nicotine at a dose 
of 0.5 mg/kg and menthol (1 mg/kg) showed significantly more conditioned place 
preference than mice trained with nicotine (0.5 mg/kg) alone (two-tail t-test, p < 0.05). 
Figure 10: Conditioned Place Preference (CPP) with Menthol and Nicotine. All data shown are mean ± SEM. 
A) CPP was measured for nicotine 0.25 mg/kg and 0.5 mg/kg without and without the addition of 1 mg/kg 
menthol. B) Mice were implanted with osmotic pumps administering either saline or menthol (1 mg/kg/hr) 
and trained for CPP with nicotine (0.5 mg/kg). 
The effect of chronic menthol on nicotine reinforcement (Figure 10B) was measured by 
implanting mice with osmotic pumps administering a menthol dose of 1mg/kg/hr or saline, 
and then training mice on the CPP assay using a nicotine dose of 0.5 mg/kg. Mice 
implanted with saline-containing pumps showed CPP of 123.3 s, similar to what was seen 
in mice without osmotic pumps trained with nicotine (0.5 mg/kg). Mice with menthol 
containing pumps showed an aversion of 63.4 s for the nicotine-paired chamber. Thus, 
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chronic menthol significantly (two-tailed t-test, p < 0.05) reduced the amount of CPP seen 
from training mice with a nicotine dose of 0.5 mg/kg.  
Discussion 
Menthol cigarette smokers have lower cessation rates than smokers of non-menthol 
containing cigarettes, suggesting menthol may have a role in nicotine reinforcement. I used 
the conditioned place preference (CPP) paradigm to measure differences in nicotine 
reinforcement in the presence and absence of menthol. When trained using nicotine (0.5 
mg/kg) and menthol (1 mg/kg) mice showed a two-fold higher preference for the drug 
paired chamber than mice trained with nicotine (0.5 mg/kg) alone. Previous studies have 
suggested that a nicotine dose of 0.5 mg/kg elicits near maximal CPP [12]. If 0.5 mg/kg is a 
‘peak’ dose, then the effects of menthol might be obscured. Thus a lower dose of nicotine 
(0.25 mg/kg) was also tested with and without menthol. Again, the mice that received both 
nicotine (0.25 mg/kg) and menthol (1 mg/kg) showed significantly higher CPP than mice 
that received nicotine (0.25 mg/kg) alone. This data shows that menthol can potentiate the 
reinforcement properties of nicotine when the two are co-administered, one possible 
explanation for why menthol cigarette smokers have a harder time quitting. 
To look at how chronic menthol treatment prior to nicotine exposure affected nicotine 
reinforcement, we treated mice with menthol (1 mg/kg/hr) or saline for 10-days prior to, 
and then throughout, the CPP training for nicotine (0.5 mg/kg). Mice that were treated with 
saline showed similar CPP to those without saline training. However, mice treated with 
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menthol showed no change in preference from baseline. Compared to the saline treated 
mice, this is a significantly smaller change in preference. The mechanism by which chronic 
menthol treatment prior to nicotine exposure blocks the rewarding properties of nicotine is 
unknown. However, understand this phenomenon more in depth in the future may lead to 
novel new smoking cessation treatments.  
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C h a p t e r  5  
CONCLUSIONS 
Nicotinic acetylcholine receptors (nAChRs) are spread throughout the central and 
peripheral nervous system. In the brain, nAChRs are primarily expressed on presynaptic 
terminals [4] where they modulate the release of other neurotransmitters, including GABA, 
serotonin, glutamate, and dopamine [2]. Receptors containing the α6-subunit in particular  
are primarily found on dopaminergic neurons [1, 7, 14], where they mediate dopamine 
release [9-10]. Because of dopamine’s role in learning, reward, and voluntary movement 
[5, 6, 8, 12], the selective expression of α6*-nAChRs makes them an enticing target for 
potential new smoking cessation compounds or treatments for Parkinson’s disease. 
TI-299423 was developed with a number of other compounds by Targacept, Inc, in an 
attempt to create an agonist selective for α6*-nAChRs over α4*-nAChRs. Because an α6*-
nAChR selective agonist has not previously been synthesized, we theorized that such a 
compound would be useful for smoking cessation, with fewer side effects than varenicline. 
Several compounds were assayed for their effects on locomotor activity in mice with 
hypersensitive α6 receptors (α6L9’S). These mice show an increase in locomotion in 
response to nicotine [3], allowing us to parse out the effects of compounds on α6*-
nAChRs. If a compound fails to elicit a locomotor response, it is failing to activate the α6*-
nAChRs, and thus is not selective for those receptors. TI-299423 was the most potent 
compound tested on this assay, leading us to continue researching its effects in the brain.  
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TI-299423 was then assayed using a battery of in vitro tests. TI-299423 was shown to be 
more potent than nicotine at both α6* and α4*-nAChRs. TI-299423 appears to be a partial 
agonist at low sensitivity α4β2*-nAChRs and a full agonist of high sensitivity α4β2*-
nAChRs. While TI-299423 is only a partial agonist of α6β2*-nAChRs, it is apparently 
more potent at these receptors. This suggested that, at low doses, we may be able to 
activate α6*-nAChRs without activating α4(non-α6)*-nAChRs. We tested TI-299423 using 
Neuro-2A cells expressing α6-GFPβ2DMβ3 or α4-GFPβ2DM nAChRs. Using this method, 
past experiments have shown that nicotine has a lower EC50 for α4(non-α6)*-nAChRs than 
it does for α6(non-α4)*-nAChRs. TI-299423, however, has a lower EC50 at the α6(non-
α4)*-nAChRs.  
We then tested TI-299423 on assays intended to measure the effects of compounds 
selectively on α6* or α4*-nAChRs in behaving animals. We repeated the locomotor assay, 
using mecamylamine pre-injections to show that the effects were blocked by a nicotinic 
antagonist. Additionally, we used a temperature assay to measure TI-299423’s effects on 
α4*-nAChRs. Nicotine induced hypothermia is mediated by both α4*-nAChRs [13] and 
β4*-nAChRs [11]. Mice genetically modified to have a hypersensitive α4-subunit 
(α4L9’A) thus show hypothermia at much lower doses of nicotine than wild type mice 
[13], allowing us to selectively measure α4*-nAChR activation by recording the 
temperature of these mice after compound injection. TI-299423 failed to induce 
hypothermia at the doses we suspected. Instead, a 5-times higher dose of TI-299423 was 
needed. This phenomenon is still unexplained, but supports the hypothesis that TI-299423 
is selective for α6*-nAChRs over α4*-nAChRs. 
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Now that we had an apparently α6*-selective compound, we decided to test its rewarding 
effects and its ability to modulate nicotine reward. TI-299423 was shown to be extremely 
potent at eliciting conditioned place preference (CPP), a measure of Pavlovian reward 
conditioning, in WT and α6L9’S mice. This was blocked in mice lacking the α6-subunit 
(α6KO) and mice lacking the β2-subunit (β2KO), but was unchanged in α4 null mutant 
mice (α4KO), suggesting these rewarding effects are also α6*-nAChR mediated. Attempts 
to measure TI-299423’s effects on CPP were confounded by the limits of the assay. Pre-
injections or osmotic pumps distress the animals, making their learning and behavior less 
reliable. Additionally, small changes in by CPP may not be measurable, simply due to the 
experiment design. Instead, we tested TI-299423’s effect on intravenous self-administration 
of nicotine in rats. Pre-treatment with low doses of TI-299423 increased the amount of 
nicotine that rats self-administered. We hypothesize this is due to TI-299423’s activation of 
α6(non-α4)*-nAChRs not usually activated by the self-administered doses of nicotine, 
increasing reward. While this indicates that TI-299423 is not a good candidate for smoking 
cessation, it may be helpful for early Parkinson’s treatment. Additional study needs to be 
done before a stronger claim can be made. 
The cholinergic system is extremely complex, as are its interactions with other systems 
throughout the brain. Discovering new compounds that act selectively on very specific 
receptors or subunits can give us tremendous insight into how these systems fit together. In 
the case of nicotine and nicotine addiction, these compounds allow us to reduce complex 
observed behaviors into smaller, simpler pieces. Looking at the α6 subunit, in particular, 
helps us to understand how nicotine affects the dopaminergic system, and how that 
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translates to changes in reward, reinforcement, and drug-seeking behavior downstream. 
While TI-299423 is not entirely selective, only showing selective properties at low doses, it 
has been able to offer valuable insight into the activity of the cholinergic system. Studies 
like this one, which first seek a scientific understanding of how compounds interact with 
the brain, rather than primarily focusing on discovering their usefulness as therapeutics, 
will allow us to better understand the complex circuitry of the brain and help us develop 
treatments more efficiently in the future. 
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